var title_f10_42_10912="M mode bicuspid AV";
var content_f10_42_10912=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bicuspid aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram (panel B) is obtained from the parasternal long axis view of the two dimensional echocardiogram (panel A); the dotted line indicates the plane of imaging. Although not obvious in the long axis view, the M-mode echocardiogram shows a typical feature of a bicuspid aortic valve, ie, eccentricity of closure (arrow). Normally, the image of the closed valve is centered in the middle of the aortic root. In this example, the closure occurs anterior of the center and the anterior leaflet (right cusp) is thickened. Such eccentricity is typical of congenitally abnormal valves with fused commisures, forming a bicuspid valve.",
"    <div class=\"footnotes\">",
"     RVOT: right ventricular outflow tract; Ao: aorta; LA: left atrium; AL: anterior leaflet.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10912=[""].join("\n");
var outline_f10_42_10912=null;
var title_f10_42_10913="Mosapride: International drug information";
var content_f10_42_10913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mosapride: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Galopran (AR);",
"     </li>",
"     <li>",
"      Gasmotin (JP);",
"     </li>",
"     <li>",
"      Intesul (AR);",
"     </li>",
"     <li>",
"      Mosar (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Mosapride Citrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3123374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Prokinetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastrointestinal symptoms associated with gastritis including heartburn, nausea, and vomiting",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 5 mg 3 times/day before or after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for the elderly:",
"     </b>",
"     2.5 mg 3 times/day before or after meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10497 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10913=[""].join("\n");
var outline_f10_42_10913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369917\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677665\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3123374\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677666\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677668\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821127\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677669\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10914="Headache in ER II";
var content_f10_42_10914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Management of headache in the emergency department-II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 650px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; CSF: cerebrospinal fluid; CT: computed tomography scan; LP: lumbar puncture; RBC: red blood cell; WBC: white blood cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10914=[""].join("\n");
var outline_f10_42_10914=null;
var title_f10_42_10915="Rx cecal ulcer Endosc";
var content_f10_42_10915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of lower gastrointestinal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxCztSpw+Sc5rWtkG7FSW1sWdAoyzHAAGdxr1Xx58OLbw34as76yF2bqGRbbUfOHyeY0SuGj4HyAllz68V5zvJNo6ebuee2UeR39q0raME89ar267F6ZrTgQdR9R7VzSY0W7SMKvA47VoxjDA/5NVYRhcD04q3GPlHesrlJF63AarBQZXHWoIeAAOtWk6gnnFK4WHxDk9KmjUYyPWkjQhQeDmpUBGABnJ4ouFh2zKipY48dR1p0f3sY6VZjA+6aEyGhsWU28detXEb5g5GAOCKj8vJGOp4qyqHaQRyKtMhk8EYCYz71IBtIqOI/wALcehqWNTuy/0Bq7ktEwTkMBxjmnAANjBzT48FB+VMlGATk/WmmRYCNhyTgHvUSzxmYIGye+KkDhoyGGQRVWCFBO0gOGPBWk3YuKXUfeIGzkciqksWOg+o9K0JVLbT+dI0Ydic4ah6gnYxpoeDgEg1RuYOMoOldBIgKMCMMOKoPGV6j60WGpWMGSBXO4DBqm8RAZWGPSty4g2NkdD1FVbiMFcHkVNi+YxmjPIrysxqV2t0r19wVYgjP9K8lEZc/LyKNjswi5nJ+n6jkjChR/Sp/KA/KvT/AAB4F0PWPDWn3WpSTrd3txPApS6SM5RcqERl+dieMZFeUatd/YmkjlG2RCVKnggjqKbpy0fc6FNSbS6ErukIyzAYqqdTy2IhWB9qmvpeCQorWtbYKp4puCjvuNotQRtPKN74JOBXoPw5+Hw8S391b3l0ls1u6q8eQZCCM7h2x2+tcCf4CAQQMcVUl1bVrfVVks72aGZlEZkRypK+hIqJxlNWi7GboznpF2L3jTRP7E8Z6xpNrMZ7eyk2B2xlunXH1qlBaDzoNwG1uoq+oeQiSVi0rnLuxyzH1J70ky+XLEwIO09q3rTpzn+6Vo2W/pq/mzaCaST3NOKxj2Z2iojZJLKyqo4HWpYLg4IZu3WprWWOSQshwPU96wjormVpIxJtES6LqchBxn1Nc1P4Zv4HO1iRnjmvUtORWLAj3Bq+bRJABtByeauNVxukKU7u0keKvpmoou1t3P41oaXpTROskw3P29q9Wu9KhIOFFafhDwZHrs1/GXETwQb4v9pvQj0qKmIly3ZcasIRuef2kJCjIx+FdBDqV3F4bvNGjAFrdMGlYDDEDkDPpV6z0Qpo93f3QMEyMEis2H7xye+Oy471oaDpEWp61bWbuIoWy0kh4wo6ge9ZSm6U2nvB6+TWv4BOcW2n9n/hziZLIMmAvbArp9L8Qw6Xp1zHFpsRuJLcW0b4/wBWn8X4n1qeSxQ3N0kKnyo5mjiY9XAPWhNJ+1CUwxM3lLubaM7R6n0HvVSlyStUWq3T/X77P5oU5xkrS2/r+vwGfC7UNMsvGBu9XjjQCErEzjKxnphcdz3J7e9afhu0il8U6hYaKizpKwmUyfNHbHOWwe6jtnOelc1qWkM8YaIYXrkd6ztOlvtP8yWxkkimxtOw43ex9q7KGN9nOdaSvJ2tfZNO97K199ro1ceducXrbr+Z6Bqet6j/AMJibQRQ3OqyKLeO+cARQRnq4H3V4zxjNc/8QfCljp0uhaV4dRr3U7ssJZFOd75HJ7Dv04r2rwBo2if8InDPctDcC7TdLLIeZWP3j6jpjj0ritI0aLQfFWp+INanaz0u1mkWwgkHzFOxUHk9cD9a7cRiHiE61OneCtGKtZyeqvZdE5NqK01u9kcsKyU3yL4en83S343ttuzxrX9Au9F1dtNlUTXMcQlk8r5hGOvOOlY5G5QwII7Ed69H1TxZaWul6wtnauNX1eeR7iebDbY27J+HH+RXn9ravJtht42lYDhVGSfU1zV8O8PpJq6sul7295u2kVfRK7el9rN9iUtprb+n/wAD0M+5hYrwcZ7VE6YQhicH9a0ZFB3Hrjiq5G45IGawTJqR91mlp1zLY3lvd2zBLiB1ljJUMAwOQcHIPPY1vt4q1y4ttSguNRlmg1Jg90kgVg7BtwIyPl55+XFcxEckAelaEGABntRKbWx5KgW4VyBj8a0rYYxjkjrVC3XdyvWtSzjyckEVjJmqiWox8ygcCrUAw5z06YoWIbcipUGGJ/GouNItxJkDHJFXVj+Xr1qra+nWtSEAqAfSpbBqwkafLip1jPGBzTo02++asADt0qLisV1Vt3HXPNSEsFJqRF+fd3NPKjIA7U+YLCRscqckHFWVl6gnpVZRkn9Kl2gqQoy3pVXE4l2FtwGDVlSDkfw1RiUjBHGe1WY2PQ9atS6mcoltMdQeKe6hzjPNVd5HIohlPnKXyMVXMRyEjRkEdsdqdHEpY571MzgnJximKRngkZoTJsyNk2jjnBpQMfjUzY/Oo8jbg1aJZXmYKwPTPFQyxbulWJkyuevtUIygC5696oSM+6T5eBzWfMu1BnpW1OoIzWdcIAORwaCkzJePDEjvXkVruiQlsEY4r2C4IRsHoe9eLz3HlQbBjI6VE43PQwT+L5fqbtn4/wBc0LTEsdMvkihidniBt4maNm4JVypYE+oNcPcpLeb5ZWLMx3Ek5JPfNW4ojM5L8jrV9LcKuO3er57aXOnRPRGVpUIWQrgg461uhNsfGQaSC3VSGUY9asMwzjHtWbldl6PYgVCQOOBS/ZFm2ykYarkIVztwc46VdSLITjgGpcgcrGRLMsSqMEnpWRc3TszvEV3A8hq6i6szMTJGu0ZrCudEnUOwBJzmrg4oqMo28ylNqwWBRnDkdKv6XqCy7V/iPGawLjS53nYBGDDoKksLa7hmUuDs9B2q5KNrJmnImrHpenTPFHmTDDsB3rWgvISpzlcetcZp9zI7YVuMcA9q7Gyt/wDQvMkIbjOQK5eaxyVaSjqyyHeRQQoZD0IrR065lspS8UhiMg2uR1K+lN0+3CxRlVwjDNXGsRNjGcUnK+5i3HYk1u6bVZRcMmZdoTf0yo6Ctay0LSrW3tbie9Z55ZETYvCxg9Sxo0O2t5L1Yr1tkIjPzdOe1Oit28oiRRvDcEcjFXzupJSqK6Vvne9rvfpr/wAEzlKystiHXvCd5Z+IoLXToZrmyuIzIrhf9Sc4w7dOfwqtps8Vtod/p8aFZrlyk04POzOCv5ZH411Gn6hcadbRFbgMszlZImG4on97PrWNqawzXsj2sXlxls5P3m+tNKLSl1VtHs2tW36u2m29yFNuyfT9P6X3GL4mWC7vLRbBGisrWIIkZ9e59+w/CsQ2W7CJGC0hCrnjk+p7fWujnjGDxk+lVUjyBkY5/GlObna/T/h233bbbb/SyNI1GkSknQtSs4rGU3EdsgaTcf3ZkPZQPSu08CaZD4hnm1XXQLmZZd0aSdEI9B7Z6VxcVjcXjNFbRvLKQSFQZIHrivUfCd3bTaS1rZr9n8hAkruf9X6/j1Nb0cTWo2dPorffq7evbb7mzGtUkocy37ny78W2ivvHOsXWkWxgslkMYVTkM44LD6kZxWh4D8RQaV4XuLDSLCW98UXqussvllhBF0JUAZ4Hfpmuh8QaFC02sSWKmTTobhibhv8Alo7HnHrz6VneENQ0/wAMR3EdzZyFpyWnnT78q/wxjj5VxkHuc9a1r137RqcFdWXL0TSVk7b20bXXZroehz81FRSu1b8l/wAOcQlmIoUX7sZJcOejc8ketUmAEjYGVzx710ni/WpvEGpJcypHDBAuyCBFwsS/1Pc+9VovDupzxTSQ2c7JFD9oY7D8qf3vp706/uT96SlJ722v2vs/O2na61Nqj5YNz0KUVsAo9RU6R4wR09qsRBTyelTIo2sSvHQYrmcjzYhbEK2McVqwzBSmfu9zVOGBcA9/SrsUQDAEdeMVLaNLGrE4YAg8ipABlhnrWbCTDKV7E8Y7Va3/AChgM7fSpBRNG2bDhFFalueMg/SsS0kxMCfu4qW9upIXURHr3z0qLXZfJd2N5JRtyD0qwkgJArlYdXjiGLhwrk4AqeLWo1u/szBg+cDA4I9c0co/YyeyOrUrxilOMZH41lw3gJIJHBqSe9GxgvPFJRM+R3LoUHPOO9SJxkD8c1mR3P7v5jU8chZNvIz2p8pXIaMDsw5GPQ561ZQgsCOnfNUbbIUK56dD61JvdpPlOE6Y96pEuGpoeYAaUMAO2azi+xcOTnNRtfLu28kg4pon2V9jYEqqMk8UjSru3Z4rIN0WB4II7HvTGuvl689KaZLomybpOADkmnFgeh5Fc+j4fcSc9hVpbvb3571d0RKj2NYyDYB+tQvhh6VS+1Z+lKJwehq0zF02iViNxGOMVSvB8v8As1MZc5z1qCdx0/OmTYoXEQZSvtkV4QsLTsGPQV7y/Ax2ryS1tVVcY6ipnLl2OvCuzl8v1KMNuI+3GKnK5TpzVl0+YDFLDDlMEd6zbsdrRFEoIIHUdaeLfcR7VJ5AjkzjIPariRYApNibtqjHmM1tdAomUPU9xXQ2CC4hQkdaYsKuTkVaRPIKmPgZ6VL1tYmdRNW6lyO0+Yr+XFXToUsmnC7ii81ejhf4fr6UujxPqV/DZ25Aml3EbzgcDJyfpXbeFW1Wz8q5tIGmglfym7qyqcEfz5px1aRxzqNao5iy8G6VPqzW738axeUJDcFcDP8AdxnrWBB4et1ln/dnCuQhPcetdjr9/p1zqUw0+3Fi1uTFNChyu4HnjjBrF+2R8oD+PpW86cYJre6Wvbd7d2rd1bbVlxqTtuZkfhm2RhI3AJzgGt20sliwqjMeOlNhZTGWU5I7GrVq5zk4FYWW4SnOW7JkgKFUXAHarvklEyOg7UkbLI+OhFTbsttXt1quRGXMyKJHcRucgE/gauWc7BJoioPP3j1A9qitiiDH8Ocj2qXT9USC4uCib96GInuAepHvUap37F6y2RMRgc5z9OtXp9HmjtopBh5J/uRJy2MZyfStbw09jdadHBetBmL93EJfvgeue+fpU2k6jbaILmK7KyXBckGPlSP4ee3FdFOkpN63W3/B9P8ANLQylKzaXT8TlLbSp7yS5jt4yZYF3NGRyfYe/tWZp+xdQiWePKO4jYNwEycEn0xXoVxc2kMkms2koWS4Ai/eR5fI79eBXKaoy3lreWqQifVrrIF1H97HXK+mBVSoRin729rduzb8l5Xf3lwfNv8A13Ox0CHSLGe6vLQIkCRhZZyflyp7evXr61yU9lN4g1zVtWspGgsJQkMRx/rGAwT7DkU+6uv7Ah0aDzEuYR8m1DgRSf33H8XU+ldg2hJFpyF7lldZvtAbO1UJ5x7Lz0q1JSo+zhFq9m+raT6eba/GyT3Mm1T97vovS551400R9J0+xSOTzYC3MXTyxj73vzXmniKFUtzIB9PevU73Q7/X7q7TT7gXNtHIwEjnarOOoXrnrXE6zprwI0V4NsysVaI/eGO+K53Dlfs92t/V6/1/Vuug+WyvdnnkBEM8cqxq7LztcZANd1pWq6xrnhm80jSVS3iVGkv7+Rgu8Y6M2OOOg9BXK6hZ7Jf3Z2r7d67HwBrtlAtlpWrQounW7l02nYrtnOZD/EfTpzVUasqcrxsn6X/Pr2WivuzsxKU6fNb+v1POYblT0PXvWlG6ugIwe1ZMdqoX5ST6Vbs1cOUixnvzxWbORJdDbs1H3j6dasQR+YyswqhbtIHXIAGOTVqO6G07SAR61A0mXLiJASzrkY6+1RvMsAQpkjHQdRUQucqSwLDrnPFVp3BdHDcr1FUlc1hHuasNx+5yVXOc47iq9zelXMpQEAc81DJIkUAcPl8Z/CsPWNUVLdVB3OPQ9RWqpXNIpN6FicGWUuvRueT936VqW8qQ25mlZmWNefWuIfU5pIDiTym6gjrVuLV2HlGTLFR949fxodFN+8zocW1a56LaL5kKTI7qkg/Me9aEVrcSMFRizAdTXH+H/EKyXcdrIjbGOS/YV6TZXVuCuCMYzxS9lfRHLVU6b23KcFhID+9fkdgOlSi0lK53MuD19avNcRM4LEAt09xU7MpT5cAY/A0/YNEpvqVIZGVvn/1mMVbQvtOBVe5UGNHj6g0sNyEuMseMYrFxcSnC4+ZXPygYz1zVUnc22Ig4646itFsS85x3HsKqSWzCWKSHC7jhye4ot3HFLqQGCTzMgllPf0oYbW27T061p20T7HdzuUe3X8KSVY2bBGPX0NKzZPWxjFhtJ5X3NVLq+S1VWdvkzg+orZurENGWjOU7iuZ1TTzKrRhmVWHykfwn1zWkUr6lRjGT1NSK83HMZDJjOQamExHTOOtcNoIvbDxGtpegrbyjl0+63vXqF/pEMGjpdWk4nYfwryTRvLljqRiKUabSWtzKFwSRgnimyTHac0IisAVxnr9KVo8tk9KpSOWUEQ7wT6ZFeehMD3r0F48HnoK4mRPzFRUexeHj7z+X6mc0WWFSBMfiasbOc0Bcn9azudjQyKLc3zCrQhwhwMdqWFBkVobBtBFCephN2M2JShxipGO4AjrnFSTALkjrVbzBn3qlozOSvqWV3I6kNtccZFdQviS5SxS3jRI40UKkS/6scddv97k81y8bK2TngfpVjIXaMnJ5x7VpCTi7oykr6MivZnwxTO49T61Rn86NDuYxnGTn0rRchie+ev8AhUklshIQ4+UZyKKkm3dmsHYr6TfSORF82zs/XNdDFtQZDdsY9azLW2AOQfpWrBCDjdWDepUrdDQs2O3LdR7VoWqpISQTuqPT7dpLeWRduIR8wJ5/AUsZjD7143elHM2rmbimTyRlGG3GB61nRW7R3TlQBG3XHrV8y7o+eadbkSyCOPl2OMe9Ddyo+6MtZHt7hTt3hTuGeh9jVyWdJrme6mbylKZVI1+Xd6Y7D3qOSJ4EBlUr82OeM1C8iF2HAUirV0K19USm4kmgi3nhR93rtqqbqSCbfA5SQcBlPIquJQmVXp6VBLKwJXjB5z3qnqUqaC4kZojC3Ks25h6n1ratNcu7y1j0i4mi+zyt808vPlj2Nc+TkgvyaRyU5UZyOBVwqSjLmT1JnBM9D065aHQNSi8PFYYbWNwlw/ztO4Xkjpznvz24rhNGhm8brDHNENOjswXlkLeZIzkdZH4znk4x711/gCaaw1CaFBHcWvl73nU4Ebf3c9//AK1c3q8McWp+INK0q4hsdNbdcTyqNhuHcZKgjqo6V20K0fZOmlZXT76PTXq23qlr5cq1IpytzRWj0d/69bnnsKxXV3cEYaGORo1c/dcA/eFOg8NX93b3V9aRFrK2Uu8r/Ku0dT9KTSI5b+9FrZRZYcMV6Io6t+Vd14n8R6JqVlo2hWE0i2FnMJLto4wokCjhQM/xHOT2965uWMpyhbl/FpLp2be35I6qspRfJD/hl3PD7C7SRVKsDmte2K5ypArzTSLp7VvKl4/unNdnp95jGWyOuampDl2Oc6RWVg6gnk/lUUtoWIZSNwOeKjhlBOVxg96t26godzZAPJrBrU0g7DnJit9jkEnr71mSz4UgjIHBPTmtZirxvjoOax7wKJAuPkYcGrjE1hLuR3NzmyAZsHpn2rnLqfgbiOO9W792T5CcgHgdqw7hWZiS3XtXXBaFufLt1LlkGlJYDCD+I1cRBu+QnAPfvVXTbhPLETY/xrSjKdDx2zScSoN31JLWN45BJFlG6qex9q6vQfEAm3QXA2SgY2nofpWbDdRHTPsdxCJI1BMUi8Mh9j3+lctdTFZkYMfMQ/e6E1kovVnXTh7X3ZHs+nkzxxsWGV6ZPStuGVVBDsSeuK818K619q2QzMdw6Gu6SeMIsjN83t2pqV3bqYVKUoStIuwyJcWcrBtqhipz1FNSyZAGVy+ecms7T7+O9v2t1Xbz8zCte6keKPy4vmHcmiULy5WXKLjbpckguGVfmXODirjTwzRRbQzLuwQOxrLtmklOCPl9RWjaW0e1sHnPFR7Oz0MZpIvqS249cDt2qKRCRtCAgkEjv9agjkeJJAdx5znvSQ36l1EgbceB2o5GtDNQfQfC4bzYnOCD8p7ke9Z18NrrtXhePpW0Y1ZPMY4BBB2/e/OsuOJ55Xi+6oGU9x7n1oiJWvcyJkjc5KgunQgc/SrVncTWUkUsDEB+dpOQarzILd5ZEJmcclR2p1iN8G3DMB8657U7cvvI1a925bljVLl2ixtcbyPQ96RT0Ocjt7U4qDGAp5PWmXSCOPAYruHahanLJAMSEgEda4eRMniu3gi2lSeHxyK40kEgisaujQ6C9528isyYxgVHwOMEVeIGePzqJ4snms7o6iFc5GO3arizAAetVsbQfaot+AST06U7GUo3Jrt8pxwPash5G83HIpX1D/SGjfr2qF5NxBbqD2rRdio07bltJG5IapY7hwTnJP1qtHgRkjGSeKC6qMZyaFcj2abL9n5nmlmfOTkemK1I3JOcVjQybcAZrUs5o8Asefeok3uTKBp2/wArZIxgVaScBgOcVkPeruxnmpUmVsEdKh+YKn3NpLshhg1KsjF2KnKk1lxcYwefWrkednHf0qLjskX/ALQVXJ69hXQ+FIm0+1k16WPzYgyiOAKGaTJxkZ6HniuTEUk0TmJGcRjcxAzgVHHqjweW0UrAIdyFWxg+o961p2TTauk1f/L5ilDmVkdb8Qbzdc6fqUY3Wsw8sRgAPCeuW9v61haRDLrV81rZ7TMELcnHArAvrmUXBlmODP8AOWzkv7motMvZbKZ7i2leGQcB422nB7cV0VZOevlp2+S6a3v3d2VCly07LpsaAvoXtJkjyZzJhZsn5QOq7e/1ouJwSgzj+tJYabd6rIn2SAkyE4bGFJ6nn86gntZ4I7oTxOJLaTy5G/hQ+hpSUXJuG3+dlr8/6uX7t/69Cz5hZlGTnqDUxYnOeWrJt5Wzz3HFXlmGOfvVFjOcbGrpF79k1G0kugz2aNmSFTxn1x0P0NY/xJ1K11DXgNJjMNiYRvQjnzPYdvwqWOXcPc037BBcygTrg9j71cajgmu6t/w3ZmcbQnzM5fQDcWRuUSVwk/8ArFBwG+vrWtbxwQQOFt0aZxgSN/CPYVO9hi68qFcyE4AUdau6bo11dTXMOzy5YF3Msp2nH0NZSuxV5pxcvI+edQst8ReMfMp3CpdJZljVg5Ib+E/w+1Xd67cdqrafErXEoQHbngV2t6WMIPQ6Kymdo8AjNbUUn+jDjqMEd651UeNk9euQa0PObdlWx3Fc7RqtTaVkWIBeQemT0rA1i9bBjB2uDjB/i+lWpLoRRhjgE9MVxmvTb5VyzZQkhge5rSnE3ox5pFm4uWEAeQ/PngGqkKyTvlsbf5U5oZbtBxlo1+bFWNKs3DBmJCE9BW6loKU0pNIZFaOJt2QFXkf/AFq1FzLCAMADkUtxC0MyjG1W459KS7iMUaqjHAH5VNm7G0H1NS1k/wBFVXAPofeud1clLtmHRvWrEE8sEW2TOBz+dUbqQ3BbnJApWVmddB2lc1PDVz5NwGJwK9M0jVd8fzKrAjHPpXjmnSMj47+9dVp15Iirgn3rnkrM7pUlVPSLa2jhU3MBJQffx1xWjFqiCdUkIKbcjPPFcvaXrJEiGXg8n39jV+1YXJEgCgjIxjoP8K0pbORxV42fvHdeG47XVdPu5rN1iubX5miz/rV/ve2ewFXDHCwjeNdrbdwycEV5lo2qXmka1NFBEZIj1YHqK7UTC7szcRyncB8w7itbwTt17fI5Z4eUZc1/df4Gp5TFSyNhm7Gs9GWW4eNwFdOpqgdWUACGcSMowwJ5U02zu4Li3lunkw4O1sHB+pFEo6GkaMo3bNiNkaMKqnaDkHtTJpwr7QeX4A9DUcDCO38oNlWG5XzxVOYb5hHLkDqrg4qeREOCvqS7FExXbsZ/4/6GnPHMswjiUKAuTx1981nQzXBlmDfMU7juP8a17e78y3RlUuo+8O4qHuTODWpXntJlsS0ZxIjZAJqjDLJcSmKTqPut6GtzeZHZFHy4zg9aqy2yQsCqlcnO5ec076GN+5G0R2gMeRzxXExL0zXdTKR8uc+/pXn0N5G7gIwIHWuat0DDxd5fL9S+qDbn1prJhs0sMgYn0qVhnp1rJaHQyjcqEyR0Nc5q119nGC2Nx4ro7vhSewrl5bA3moO7btmMKB0rWLVtQhHW7Ks0YuEjKs24chweRVlEcINwJPtWtp2lYUq42kDKntV+307djcvNQ5XG5LYwrS1nmfaq4rSXR5SoLPg9a6Syso4kyqgGn3IWNSeMUK7MXPXQ5g6dMpUb881OunOpBZyT9a1VxJggcVMVAHI570rXdgc7GaunLjO45+tSrC0PGas+Yq55xVa7uEAILAcc01AXM2WElIx7dKt210u+MNnZuBYZ6juPaueW8VRnPAGaxZvEIScpGCzMeAO9Pk7Fqk5bHqev+LwtpewWFtFaC5QRFouDsxgj9Tz15rz9bpYlhijwEQ4+lNzLepGd2w9eT0NUzZT7meTrnjHTFaxvyKC2X57f16vuy6UYU1ylo3xnlZRkIh65q3bTFkUrzk9a57zD5vlqduTz6mr4vGQbThdo4xRY1kux3Gla5d2MCW9tcSQxBhIqqcAHrV9vFrSwXllqtrb3NheZFwiDynfJ5YMvO6vO9DurjVPEdtpcTLGJBlnbtU2rNLpur3FlP96I8N2b3Fa07xbSe2v47/ev1Od0YuVnvuaskscdzKts7m3B/db/ALwXsD709rg/Kc1zkVzllH4k1opKGQZ5JqZau5pKPc27e4yM1p2N1A6ubp3GB8mwck/j2rnICRGRmpFn2sFJ+tZtXRyzjc3bG+uLK+gvrZoxcxElGYbgCeOh9q6/Qf7J1bxJcXV2l3cyNB++eZwAW+pOFUdgPyrz63k+T+VEl46q8QZgjfeUHhvr604y11OerC6dux4RLNJsKd8cHsat6PPuUnGGHBNReWOpAxUaqbeQunGeorqeqsZQktjp4GEiBWOQ3TNWGDIOuR6GsfT7tAMt2HIrRjuEkizu6/rWLRpsR3smUIOcdua56WymutQWNOFA3ZPSrjXBZmOCRk1o2Dosg4yrLkH1q9Y7HTCbp6or6TA5EhB5Y4I9q6PTNMZrdh02cg1m6EmxZHYEgsQBXUWiSOu8kRxjqT0on7ulyqUb3b6mPqNg0zRyMOnBpr2fnSxr710CDzHIIyvp/eqS100LNuUblB3HPaiUrM6uX3bM5zWrJUhYqv8ADg+1cQWMRY9xXsWt6Ubu0mW22hkiMrlmCjA7ZPGfQdTXit848x+oJ4Pr+VaQjeBOHtFNFiykJUOPXFdt4BitL/xHaWepzi2spMh5s42nHH61w1hhYwD0rRilK5wa56y5ro9ehFyp26nqGpaTYw6Lrs9vqaGazu/Lt0Y/69O3TufXpTLG6+z6fFLIcEqARnofSvOpLpigUsenY9a3IdSceH0iuYyjzP5ltcDo2OCre1XHkjZK+6/JL805fOxjVw0oxSbvqvyt/mzr9NujNecYKMpJPQg+laHh/WI3lnic+WckEA8Z/wAa5TT5QTG8Uis4GXAPStzT9NW9u3ubJgkg5dP71XKS1lY5dI3UjR1K1mijjuQFTcxEjL0x6n/61Yj362F0RIWeJxkup4aukXzJdEvLSVgskTFgT29q8l1CS5ju5Y52O7dnrwR7VLas5XPSwUXUupdD2rRb6LWHSGE4gADZz+la97plwIPMh3EE4AbqBXkPgrWHsLrfIrvCRhlXqPcV6zb+LYJ1AyCCBhun5iig/aPl2scOOwtSnO9Je6VXt5YVcOdrsPlI9ferttGI7dPMcK6kZxxmmWuox3MzJIPlPK5FZHi7UEtI7PaSCz7R70Sg1K25jCnOpJU+rOwWETtHLDgOvDHPBqzNAvICjjsRXH+GNaeDCSZKs2VVua7maa3ksxKjEA/eXrg1hGSl8JyYuhOhJJ7GLdRAAYXHrXz3p2oyQXAaZTGrn8K+iZ3BjYrhlPGe9ePQ+FhLt+0MWVWyBSfKviReHsnK/l+pespg6pg8HkGtKJ88/WoEsAgG0YxTzGVOzHXoa54rTU3aT2Kd6HmdUjHDdDV7StOx97ke9XrCzyillGf5VrC2EY+UfWpk+bRGVSVvdRmy2qquAgHpVYEK4QCtpgjoc9T0NZUy7HIwC/8AKtoRVtTBMJJ/Lwi4J/lVWaN3w0jZI7A8Vct7cHLNtz3OarXlxFbxM8jAAdzxQtdhXs9CNGAHIx7VW1C+SJOoBNZV3qhfmI7VPc/0rDvL9C43NuP51pGFhqOupcu9VkLMEOPc1j32qSt8hk2tkYAqndXbO+2JcZ/Oli0qZwZmyWxkDvWiilua88Y6ll79CwRpDuxzg8UaVLFdajFDb2slxMzfIqKSWPtjk1zN8ZIp2EmUPpV7w9rF/o13/aWlzrBeQIyq5AJwwwcA9609jaOm4pVeVHX3niC1tr57eWMwyRny3TB+Q9wc9DV6bU47p7W2tzuaYhEC/wATHoK8tM5mleWZzJNKxZixyWPqT61ZtLiaIq8crpJEwZcevqD2rSdNRfu7IUYxav1R1epx3FhqssN1BLDPF1jdSp+opkd0Dnd06ljVe51z+0WE1/PJc3O0Au3LYHYmrX2vTLnQ4rWKNotSEhb7QTgOn90jp+VZON7fj+vyHCvdJSWpXF6bW8S4gkKTp911POKmu9SnvPmnYyyA8OeuPSs+WNXYqg+ZeoqS3DKwJzjNTezudis1c1rRnUKz4G7oD2rTt3KdR83rWVAfNcAnoOM1t2sC+UpYjj3qWZTfctwMQVPPPWpducnqfWuw8E+Dn1m5eK43wIEyrMp59R9ea0tR+HU8Eky219busSF2ZiFVVHqScCspTULN9Xb5voedVxNOErNnCW7lTgipJYw3OaoWjvdXCLbh3LSGNVCklyPQd/wrTmgeG4aC5UpMpwyngr7YqnGzsFVNXT3PFwOOfWnbBnpT7cB1JHQcZokBH3Bnsa6mcMdyLydhBXoTT4WKhhzT8nYODijhgOMGkaxk0VlQlzz36VLFI0NyCclMdM9KcB83rnpTJ1Dp3BU9aE+5upXOk8NJ58xVTy54rsdStStlDFCNzFxwOcjuc9q4fwrJ5UiMxx83Neh6fdxf2tYwTsUspXHmPjJApNOU79jaEuW3kVbS2blUGSK0Y08mPIOCRW54lmtdMk1PR7GOOWwuwssc6nLxvgbsH04GPxrmROQQZvmA+8OlONOVk56Xs/OzSafl/VzeNZuN31I/EtzFb6A7Sswe4TELIQQpHXzB1+nSvDHG+Vyxz83r1r0PxpfhLdkV/kYkgegrzVXzIcDgnIrqd1St3dzaiktX1LyEqoxxVmNjnOeKqI2QBUyOAuMGuKR69J2ZYeQkimm5lZNgc7F6LnI/CoGbOBz9a3/CGhyazqaQInyHqe1Tz+zXM+hVaqvkihp8120yx2vmGQ84Xmuy0vxS+kzW5ULJMo2zg9//AK9dLrnhWHw5p3l2ihrp0LGQ9cYryAuwmLHkhsnNVSk5w52rLou/n6HJRksR71rxPU/+Egkk1Z2aMRi5jz5Z5/GqknhuS+Dzy8SyH5UA7VT8KXo1LUknlRTJGu38K6a11UnXjHIuEXgg1nOU6jadkra/5I6PaOPu01Zpfgcfd6be6ZsljLMo+8yrwv1ostQeL/lsMMcgHtXomoJCthdAqFhKnIPPNeQyqYJmQnocikoShHmTOrB1vrEXGZ6fouqxXIjiB8uReCCevuDWd8Qr5Jbi2SGUMIuSoPQ+tcha30kSLJuIfsPSltGNzdEyvkue9UqySbZtTwUYVVUXQ39M1u5MsYRcyfdX3969V8PXkr2xaXOAPmB9fWvM9JtBHcqFGSOcgdK9V0EobdYyA645OOvvXAqkrpRRw5q4ez0RoLKJAuFAcdVPcVzbWqhDgda6Vovv+Sd6DkY/h9qyXGFHeuib2Pmk/e905+7X7OmXHBOKesSnbxk9qv3FqJWIfOB61XtLfMspbO1eFNZN9Tri1ylu2j2Y9KsSNlenFQOxGweoqC7n8scccc1agYyVxksgQsf0qjIdztI2PrURmEmZWOFXpXLeKvEi2qmCAgzuOBn7o9TWkYucuVE8r6Glq+vxWvyod0vQKOtcdqGr75C91ISc/Kg/wrlL7XD5xSNy8rH53Pb6U2ydHk8yZvMA5IJ610qkoolyitEbM2ptOw3MI4wemetLAxuGPlqCp7npWe8aMny8Z5HtVvTnMMQVj8w6Cm42WgLVG/oeivPcqfLeRgNx2LnCjvXo/hPwVLr0L3albbTFyWncjAA69ev16VxPhjxFNpWm6haRFU+2rskkx8wXGMA9uK6jQvGV9peiw6bb+XJZqSNjDhgT0J9OazTu9e6+7q/W9rfP5xVhN3UTz34maVb2Ot3Nvp8i3VpC3yXCcrJ9COK4p43ih8w4Ktxive/iPoeiR+HVvtHu0k1CZg0tluHygjlk7gA9jn614FeB7e9Mb52Z6HpXfeMoxqR2f36W37X+7sJu8Lx6EkOlXrWsmoi3lNlA4WSUKdqk9iegpyz+UzSRN1B6c8V6t4W8WaPc/DLXPB2pyJZG4hJt7hULGRh82GPY5UDPHBrzix0/ST4Kv7tryVdct32rbHGzy+xzj5j9DxRFKcbve9vk9n/n2OWFZp+8upY8DaPd69frZadGrvIC0jMcLGvck9q7LxB4JhsIltrbUYrkoSxnSFhz6dcY96z/AIa3UdhoCG3fFxdMRKw7Adq9G06D7VFypx2OK5KlXkk7nFXxk6dR8p4lObnTdTEcwBdh1U7g30I4rQe5R0AUHNeweH/CGkXXjCJ9dj2WPkuwYttUSDpknpxmvFr68jn1y7eDDRGQhSBjoT2reNOlOhKtzWkradz3sBi44mnrujVtXbzFORz0NdBZXI4DKOOea5W3YMyknOO9bNnLGZFHrXLa+50T1PoDwrdv4k+HOo2tyz20VnGFSeAlZGK/NyfXgA4ry++1qa8u55IDPBZOoRYnkJZuOS/bk9sCuo8HeOToPhebTbOBHvXkaRJXGUXOOq9T0PeuIMaqZmJLNLI0rluu4nJrWr7N042+JP8AD+vn6HBTppSndddP1NHQNPe91CEIxhjU/POAcQjHU4rqNf05tI0q+tYtWtpo7xFdomAE06kcnJ+ZMfrVTwX4gj0+wk0q9ST+zpyd0kGBIuTk8kHI9sVL8Rtd03Ubqzj0a2RI43Ek91ICJJgo4THZfXjnjGKily255PZ7f1/XpuY1VKUmnseB26jZjAwPSpCo2j8qpxTbSoPrVkMzYyDTbOflJDCSo2iozATIqgHJ/T3q3bkgdMipZIhKm5TyOMip5i0mZMNvPEXWYZXd8retTGI9xyetXgJHQROuD296tR2e4hcduKTkW7oy7Bns7gMFLpkZHpXf6bNBdyxTxHcn8Y7qa5U2JIzjjpmltzPZys1uxVsc7eh+tVGavqDfMdfNOVeUFiRn5STWTfXzRQuM4JHWse41S4U73GRTLq6S8txJE2XXkxtXVzR6anRFxVm2YWvq10VTJ2jvXOSWskLfMMgdD2NdrBJb3W7cuyUdQalu9LSe1ZEUb8ZBHes5Tk9zoVd8yucVFnABqYKRz3q8bBlJAB254+tSLYSsuVQswGSAOcVzyke1SnG25o+FdBi1iTbI+xn4U9s+leleDbaHQ79LC7gaKRW/1p+6R65ryO2mktnUxOylTuyOxFe2aVdR6zpVvcsQbkpscn+Ie/vWLgpu0uv3GONhKMebozZ+J80UGirLlPNClYyDywxXzpcA7iwGMmu/8Q6neeTLp18zMsbERn2rhvJMspB4APy+/tXZVlFQUUXgafsaDTdzT8IzPb6khBIDcGvQrobrlNo5C54HX6V5zokZ+1AfdYfoa9F08PPalGz8gyp9PcVy6Xdx1rc3MuxvRWTajoRt5pSD97cOpHpXlWq25g1CaMjocCvSdFvnkVY0YhlJ4NZusaGl1dzTeWUB5UdwfU1VT3YO5tgajpVGpbM4K1gkmmWJB155rRtdLmM6YU4J+92rVsLKNJsTpjnBP+FbFncrIskESZ2NlfpXHyzd7HrSxDvaJ0/hrS/KmiklALBOhPWuwjhVUyoAHr7VmabDFDFBHExcMmTI3UH0q/A7nT2WJcybuh5z70UKK+J7nyuNqyqTb7f5jlcWczmJf3TLkY5zWYXw3ABNX/JeSQFmZVHO1fun6VQFuWIJ4PtWla2ljkSXNq/61ElbMbA8MazlDBDtOGB71qzbRGenAxz2rHnnSOAlWBI71MYO1i4vsNnusfKRhh7dazbqfecOcJjLEmqSamt7deVbMHVTtZh6+gqPxBNHDZlVI8wc4z0+tbbSVNblNWaTMTxR4hSxtTHCh2nhWPevKr3UXuZZC8hZ3+839KseKdUfU70gH9zH8ox3rEKHI9utd9OkoRsceJrqP7uHzJJbcvH+7GWPSp7O3nihDeYS3cVJAQi/rVqK4AOT3Oapts4k2tgiuZEwH/8A1Vftpi7By3A61VkCuhwPx71XDtbbgMFSMkVDipG0a8luaE+osHPlueOtdNoeph4o4m5BHU9686abMxY5wR09a3NCu9syhjjHSoq07I7Y1I1FY9BlkJ+bfkH19PSuP8UaeJD50Q56mukR3ltxjk47VT1G2eSHOegrKFRotJM8+JfeEycjv61tXVjaw6Bb3sExad5DFNCf4ff3FPvLD5vMAwR2FVrohIDz26V1wqJ2OGpQal5C+FdQlsdSigds25fIHoTX0T4cYPbRntjNfMEA3XC44PUV9B/D6++1aXboTlhgHFceMWqZ5WYUbJTR3ZhknbbDCWjA+ZjXjnxL8GTaZcPrekwMbfk3EYHT/aFfROmRqFUsAMLz9Pf/ABqzNZxPbyR42K4II6qwNc0KrhsefhsXPDzU4f8ADnxlb3m4hUbAYZz2rZt5fKljI5+nrWn8TvBEnhfUmv7WMto9w5zgcRN6fSucsrxQuGYewzXVLTVbM+2oYiGJpqpTOtsb3DBQ3U+nStSWZWlLQg+X23HJrkLS7VGyhBz79K37CdJFCluvPNZ3JqRtqb1tIpXIGAe9aXhbQ5PE+vrZZItEG+5l/uJ/iaxoJEjiznvUMsmHLo5QEc4PWoi7SucdRXi7HlcEq7wo59zV2Kdd5BOdtc+PMjIIPOamjuWR9wyCetdriQo3OthK8dPeraDA2jAXHUda5e31AJhjknpV/wC2tIY9km3DDOTWTgUoG9CQdo64OPepbS9gkuJ4EYNLCcOD1ArKgug178ygBehq6v2b7RJcOqh3Xa79yKyasDgbSlAhOPlHBqGSALkryD0prYjtwkb8gcE+lSxOfkjIPTn2pIz5Oxm3tuHiZU7j9axGsZlJMR/DtXS6hC6ozx849Ky1cyIdww61tCRUdjn7tHAAfKSDo4qbSdea1m8m9XBHBYdD71t3VrHcW8gPyvjKn0NYem26S3Lx3UauVHetOfRmtOokrSVzqYre3uWW4hwQwyxXofetT+zE8hWgb98h3K3f6Vgadplxp0vmWcoML/ehkPGPrWg+pSWN2oEbRN1ML9GHsazXLJ6nXC8rKDM/XNAdXe5tlByN0sQ6j3HtVTQdVudNuQkcpWM87c8V3lw8OpQxXFq/lzbeCfTuDXPanoUd9KBgW96R8uPuSf8A16iUWtUd+Hxd4+zqozNf1KO8cLKfmPzBwayr2EwTqAdysARUGqWc9leGC5BDr2NdZoWlw6hp9q5+aV8kn0x2pTqbM7JckKaa2MWxtJfPimUEhz1Neh+FLlZNQaJsbiMEHsKtado6xPHDt++v7th0z6GpI9H/ALMbz2AE4bcG7GslJy6bnF7ZTVpfI0L+wg0nUVng5gI+fjoalmni8x5yV8mRcBuwNRX+rG9si00flyRZ46Z9640XUjW8ip8oZs7h39q3lGMdWb4TDyqR996oznu5UnmjkOcSHafUVseFzI15HkfLnaWNctcM0NyFfILciu48DTW9lpM15KwkmJwsfoa5q9RybUVe7PbxCjTpOSV2egWKxqywjgp90VdE21Zojhc4wQetc1BNcRXEMzHcs4ycdvattSZwsv8AcPOKqCUHa58pXotO8i6gd2iD7SuPmOOlQuoVeOppWuPLZYxgGXqe4FZ97exrkZ4FVK8rNnE4tyKeqsbdD8w5BJBryzWNfe4aaO1kVIVYoxPc9xXVeLNQmaF4oVLOy8k+leXabEr30qyZCnlt3QVrHlUHLqejQp2jzM9D0u1i0/Sre7lmVppBkxj+BfU+9cL458QFLeVImO+U4AzyFqvqWvb5Ps6yEQxcAD+KuE1vUGvdQLE/Kp7VWFovmcp6t6/LsY4j9zFzb16CRP0HJJ5zV6CIbAfXrWPHKA3JHWtCGbfjDYArsndu54yVy+LcMwA6DimSxYPHbvUP2xUkAB+bpio570D+IA+gqbMLJF6J8AKep5A9KawD55BzWWs6yRkh8Y7mpLGf7JLn7wPPPIzRysLovPZMUDbce5psQe3YN6Grc+rRz28ETIiGIEZUYz9fU1NqM9pcWtvHbkqyp82R/F/Wlq9GVGVnc6XQNQWWBQTg1rySK8ZA79q4BrsRWkKW4KOmSTu4J+lW7PX8FUn4Nc7pW1RtGrd6nRTQjeQRyaxtV08MjFOnpV4XiyqrqwNV7q4/eY65pJNO6Ojm5jDtbMxzqWGQD0r334aeHWl8PSaxZTLJFCzmaIjBXb1K+v04rxkNGxGcY712OheLdQ0nRTpFoyx2E8m6bH3mBPIz6GnL35R5trq/p1OPFUfaxUEfRGjTLdwRPG2Y3XcpHH/6q37ZCFBAVVJ6jjP+NcX4Eu4ri3xCQYwBtA6Yruos5Hqe/c159PdnyqjaTiyhr2h2us6dLaX0JlhlUqykcGvk3x34JuPB2ttaToWsZmJtpj6f3T719mJjOBjPoBk1g+NvCtn4n0WawvYwVflWA5RuxBrsh7q8j0cHXnhJ88dnuv66nxkluF9Rj3qa0u3tZF5+XPHpWr4l0G88Na1PpeoqfMjOY5O0qdiKwbgMrbsZzxj0q3HufVU6yqxUk7pnWWN/5sXB69jV1j5kagdK4+ynMQUetdDZXK+WPmG2sJKxlXjyxdjz2AgklyOuKufZlZSSAF9fSs2OQJIy4BArQjuUeFo2I5H413bmFrLQktDF/qpkxkfeI4NNmUQtnII9BVc3IdlTgY4INMkuAgw+0jOKOUcZK5bS8YsJEfPbbnAq3aaq22VbheQOBWAWCMHRxtP8JqCW9wwOMGk6afQ2bjbU7W11tGjUAlW6YIq5/a0qLngr2xXBRNK7dGUE5GDWjE0+ABnA9al0kYznDudZ/bqFACSGHUHpVZ9UtWYluD3xXN7ZnP7w5pUhO35+KrlSMHUidUt3ayoHjkAxwcVkySi3v0lRgwBw3uKxJoXViVZvwNVC84kVQ5JJwB1qlFC5z1rTZVuADkFTjFTajZC4gkjlXdGeg7qexHvXG+GdWeyuIrHUsRyMN0ZJ6g16Pa+XcQHpxXPODjoXCrbVHDadqk2kztBdlmQNw+O3rXdF4dQsFkQLKGAPHb3FZOp6TDexurqCrZIbunuDXK6Tq154W1F7eceZADyh6Eeo96Iy1sz1YtYlXWk1+J0vjbT2ubKzuCpY8qJMfMPYnvWT4M1R7C8MTY2njaa7rR9QstZ01/LAkikz8p6qfSvMtZgfTdedG4Odyn2oqU7o6sHVc+bD1Nz3qwt4rvTbZ1VldDu3Y4rUS0j1K4W1KbcLuIP8QrmvCerGbRbeSB/lcBWHuPWu401Y932o/LK67Cp65+tKjJOPnqeXVcqbafS5yfiPTYpkkSNNpHGAOgFcvDpkSRhrkfIjbmTpvHp7V6asXm6jPFjPlryx6E+lcf4ih8lGJXPJAxTqU4yfLHZHdg8TJJQTPKfEOVu5AgxFv3RDOSi+me9LoV3Kl1siJ+btnpWl4s0/yYFkUHnnisHSJWjuwi4/eADPcVzzXWJ9JTrKVNJeh7DpUztZRBm8xwOOOPwrbsbhxG7uNu7kj+6K5DTr5YIVyQUVRj6109k6T28aMMCQc47URheKZ4mKjq3Y1po0l23EeGULjnvXFK0kjo0+4tngdq66Cy+xQERu7RnkbmJx9Kz73S59OvDbXvEy/N0AyD0wB2qZU5Sg5p2S+/5em7fQ82M4xm0nc5vxG9xcopVUVwNuUGABXCavo0huU2tt3feNekX23YfQHNcd4ov0tbKSU/wjNVSUuWMV0NYVnHSJ5j40W105/Kt8mVvvHP6VwsrHzDtyAfetTWbxdRllmlZzOXPHYCs+G2llyVBwoyTXsUoKlBJ79TysXVdafkv6ZCHxkNyexqeG4baFB249KrSjDcjmp4I8qvb1rRpWOJSaZLGrMck9ferDxhEBpiADgjpwaWQ5XHPFZt6l7kcILSFiPr71ejwoAPNVrXbsJY9akILfdJGOKGxJD3w3IHXoaZll6Fs56g9KEkwdrqcipiATkY5pNlERllAPzcehqtM7sRknP16VfIAHIqpclV696E0F2S2epTW/BZmXpgmti21NJgPm5x0J5rmeMUq/K2QcHrmlKmmVGtKJ2Kzhe+B2960rO7DKMtgj1riLe8dGAckqDmte2vFkGFPvWEqbR0Rqqeh9FfBbVVMTxsSWVsEZ6+le62xDpn17+tfJfwh1ZYL25gaTBYBlBPWvqfw9cfaLGCQEfMv5V5s1y1mjwMdDkxL7M11Un5duWH8I6D61NGoJxuGfQLmmqQq5JIQ9AOrVKjFQCSI1/ujrXVCKT1/r+v6QRSOM+KXgK28YaIyLth1GEbrafGNrehx2NfI+pW9zp+oT2Gowtb31uxWSNvX1HqDX3kcMOjHPvXj/AMdPhv8A8JHY/wBsaPEqa1aqT0/16D+E+/pmuqpTS9P6/A78Jifq8uWXwv8ADz/zPmcgbcZ2t2p4vfJUB+GqPblMSqySIdrI3VCOoNZt9JubaOSDXHya2Z7kmpRaMqUBX3epqtPcBXBX1zwOhpbudWbBI471WM6u6JGP8K7oxOVzsEtzJJMZHOCevvTI/NnbahJGeT2FRXilXwGyK09EXMkbbdqYww9TWj0VzBybFFns2mZ8g9e1XLewin8uUAMO1LqEBlBXdg4wD6VIL2GyijiPAAxxWXM2LlbRb8mOIHGcn9KnjDhxkcYrFF3JPqihWzFjOK20lVsN371DuhctiaRRtHH41SmYxkDqCe9aBdSpz0qhdRhmBJyM5qUyUrEbMG46Z7Gsy4aWK9jmtyq+W2VJGefpWm6ZO4H2qB4iRng4qo6D0Mud5Zrlprhi8pOc+n0rp/DfiqfT2SK7ZngB4bqR7H1rGltC6hk69apPGyE57VejVmCdtj261vILuETwsGjZf4T0rn/G1gLjT1uIlJlh9B1WuD0LWLvSpgYMtET80R6H6V6Ja6lFf26tGflZcMp4I9iK5503F3OmjVcJJrocRo2q3Gk3cc9tIQpOWXPBFdR4uu7fWLuCa3GH8oNkd6yPEOjrHJ51mPlPLIP5isK1unieMg8Ient6URl2PcpzhVaqR3R6D4K15rGMwbhsJzg9jXs3hjU1vbVTIwbcQPpXz9FYedA1xa+vPPSuv8FatLZT+XcM21cZHqK5n7uqHiKca6co7nt9lPHLcXi/xRON3vxWH4lsDczI0J4Y8+1VdJvluppriCTPm4BA74rUjDSgtnGOOf4a2g9X/XQ8tL2U1Lsee+Nrcrp4K4JHymvMYWMU6MD9017F4ljE8yWy8tySexFeNXi+Vd3CDtIRTqQ5UkfQZfO8GvmdVa3jOItx+V+uO1dj4bu53uY0cnywea840uYsY0zkcfhXtnw+0mK90++mQhykkZUgdu9RRUpTUf61NcfUhRpc8kdndaa8eiC5cfex8vcZ71zfiu8a+1+4up8b1Xyo1H8Kf49a9J1oRro8kLEDeoRB79q8Re5eV9xb5j1J6muuvFUKXs/5t/8AL+t/vPisLVdWpKb6bfP+vxKmouyJg4wa8l+JuqCC3Nsp+ZuTXp+tzbYGbI47V4D42ne/1SUqchTjFRhYqUuZ7I73NqDktznbfDjk8k1t+bBDCI1wCBzWDEjI4OCAD1rbjhhkKSHLZGDXVV3ucFNe7ZmPL88rE8+9TQcLnmmTqEndV/Cpo84AI4xmrb0MZfEOULySTzTzESuD90d6jcAnBG33FJ5hVdp5B4zUtFIjRQHZG7/rVqJlxheKQorou3qOlVyzRsAwznvS3GWJgHwwI3elEEu3AeoYmVi2etPAEjHAG4UeTGXgUOfTrVO6UFhnpTg3ljD8e9RTNkA8UJakshdQH4/EUmOc9qQ8E5xz603cR1/KrIHkdgRg06OUxOCpA9ajBxk9vpTF+Y7scelFu4HRaVqbW9xFPExSRGB4OK+0/hnrEeqeHbSZCCCg4Hr3r4PX5WyM19S/s/6g9toNtFJJvLHgDtXm4+mklNbpnHmD56ab3TPolGZsbQDKeAOyirMMYUHb8792NU9PbcuF78s3oKuq24FYeEH8VXh0mlL+vl+rMabTVyQYB+ZiT6UpG4YKnB96avH3Rk+pqT6n8q7Ye8v6/Nmx85ftA/DlrdpfE+gwEj/l8t0HUf3wK+erh1I3/wB4Y+lfoZcQR3ETxyruRxgqRkEV8ffHv4cS+E9VbU9NjLaRdPkqoz5TH+lYSp2dvu/yO7CYnkXsp7dP8v8AI8bS0V48ucnvWW8XlyurOAR0Oetb0ZG7P8Pp61WvrBJAZAcP/OtIytubSMVnLYB7cVraQWjjZueTjHpWTkpIQ6g+1Tm+fCqmFA4rSUbqyJUu50aTr0c8n3qnqCpwSRkcgmsqJ8yebMz7cHG085qEXMrHax3LnvWap66Fc6TNezUIm7GGJ/L6VoCf94Oe2K5sXr7gM47UsV23m/e5J60Ok3qHtI3OqW8ATaDknjFOjuA+QfpWClwM8HJFM+2sJCp4waz9mym4nR7Rg81c0mSxiv0bV455bHad625AkJ7YJ4rmBqKquDISBRHqioXLYk3AgBjwvuMd6OSTIdmdRq0NrZtYpYXa3SSw+bMdhXyXJP7vkDJAxkjI9DWPcgNghfr7VVjuFa0YvI4uAMxE8hvb/wCvUdtO0kR81v3lU421EkuhNb3b2l4k8O0SocjcoYfkeKtQavey6yLkMnnTsEcYCIe3QYUfXiqbopAORkCq7DHJ7U9wtZ3PRoLxZC0U2UnX5Sh/oe49xxXMa5ZfZrnzIhiGQ4+hrFS8mEqzLI29OASc8eldHb38V9BtlHz4+Zff1rGVO2qOvDV3Tepo+GNSESiCbAHT8K63ULdVijniXEg6Fe4ry+Q/ZpCobkcg+ort9B1+JtJFvdsd68KTzis+RX1PRld2qUzq/CepN9nE8Rw6tiRc9feu9tdTWS3lVyF3DP415J4Wuo7a7uIdy7HHmFif0HrXWNcmSPKnHGOPSnCNpNGWJV5mw2JJXmbqBtGa8c191TXrvaAy7/1r1G/vIn07aGKvtx17ivH9TkLahOzHLFuxq5q8Wzvy1vmb8i7YT7JQR36V6z4F8TSaVNGLeUR702uDyK8csiuQSa9C+H+jnX9aisY5BFI8Zfc3QgdhXKqnsnzroehiVCdNurt1PaV16TU72N3ZX8pDhE5H1xXm1xcxby0eFXtXe/Cezh+265bvtlktZ/IMgO5SAOgPQ14T/akjoWU8DjJrWrWq1E+eNlotd+/y3Pl3ThGo4UlZJJ/fqWPGms/ZLCVlwSRgfWvFGvXlldupZvzrs/HV20toi55PNcZpdv8AvULDIz0rpoJRpXZNVyjyxRtW+mNfWifZ4wMfeYnqaq3mn3NrIEjO7HXHau60pYooFVQqDHNLeWseGkjUFj3Nc8azvqZp30Z5bLkTtuGD/KpIpARg4zniuhvtIMjtIFyx9BXOzwPaz7WXn1rshOM9DmrUnF3RJKcDjB7DFRBC/A4P8qVjsX5+CO1LC+D05IqjJCbZIgCMkVJHKjugnHyqfmx1qaNlZc/zpv2c3T7YIy7H0GaN9wu0PuLKIQRz28gYSk/Jn5kHvVdUeJyw7UeXJGcIeQcYNXtFmtINQxrcEz2xGG8ogMD6gnik7j5rIqtMrYBHbvVWYjnGCPrV2/jtZJ5zaErblsxb/vAe9ULiF4xuwQjdD2NVBX2FcbBMY7iOQKGZDnDciiafzp3lbaCxzhRgflUDFs88fSmhua0sQ2TscgjPNOQgDGMYqENjBFAb160rBctxENwcdcV7n8FL+ZLttNRlVWUOHPUe1eDK4x6EV6z4BvIjYW13ZzBL6FgJF9RXFjY3pj5FUTg+p9iaLMstsiI+EAAZvXArdiYSL8vywrx9a828Bakt7aAeaDGg3sc969Bs5RdKrL8sCjjtmuLCT+z/AF8/I8mi3FuD3ReXn7vApwwPrTUcOPk+6O9OGAcDrXsQasn/AF8jsF5rM8RaPa65pNxYX8SSwyqVIYZx71p4pCB+NXOPMrMR+bUERidWJBjYcj0qpqdw6LsHA6j6VfMUittwQO3vVaaEMSXUN9a5U9bs9pwbMEyFyd351es5oo7S5WaESPIgWNv7hz1rQtIYUnUSW8bL7qK6G2isEkCyWtuyjp+7HStJVV2IjhnLd3OGEcmBgE59KY2UyrDk17Dp9ro7BStpbPkZAaMHH6Vaj07RZpmMmm2QHr5C4/lWbxKT1Rf1WT2Z4dTox8wHevfl0nw2y/Lp+n7va3T/AAqreaNpKuDBp1gQe/2dP8KHi1bYhYCfVniiDaDgkZ60jjJyTmvYn0ayYNJ/ZtkFH92BcfyqxpWl6XcuQNLsmZeqm3U5/So+trsafUJdzxPkYHanLjuBX0LD4c0xmA/sfTiP+vZP8K0YvDeiqmToenMx4A+yx/rxTeLXYh4N9z5sRyuCpIx0zT0lYZ755yK+n4PDOiNgNoGlD62keT+laMPhDQcDd4e0rP8A16R/4UfWYvoQ6Eo9T5US8YcGnG6Vh16V9Yx+EfDh5bQNI47fY4/1+Wp4/BnhtyMeH9H/APAKL/4mhVovoQ01ufIxuFHIoS9MbhkOG9a+vh4J8N7/AJvD+jdOMWMf/wATSt4M8MqMt4d0bPtYxf8AxNV7SPYjnsfKsN9He26h+JvQU+xucExscdvoa+o4/CXhtHB/4R7RwP8Aryi/+Jp58JeHCCV0LSc+1nH/AIVEnFnXQxrpb6nzhY3bxSFR9GH+FdbY+IWNwlsRhWGFz1B9DXsf/CL6KDldE03d6i1T/Cnt4b0cuG/sjThIO4tkyPxxWW2p2SzGnU+KJ5Bqt6y25UHGTnPpXDTShrhmGetfSNxoGnyAhtNsie4MK4/lWZN4a0oHcNJ09fpbJ/hRJtqxeHzOFJW5TxjSrNpE8w4wBivRfBVnJFcxzQsyyDIUjgg1vnSbSIfu7C1QdwIlGf0pybrZWayLW5IxmE7Dj04rncGaVM054tJHa+EbS/0ODUr4wMkZt2kbcpAY+v1r51lwgYY+WvSZdY1cK8Euq38kTDBja4cgj0Iz0r5aOraiRg392R/12b/Gu2K+sJrre7b63/4Y8ypiJRm5z6/p/wAOdn4njDxp6ZrLsFWIDjJBrm5L67k4kup3/wB6Qn+tMF1cDpPKP+BmtvYPl5bmU8UpdD03Tp0dByPzrYiAaPDZ/HvXjiXt0hylzOv0kIqYatqI6ahdj/ts3+NYywcm9GH1mPY9ZEKljxWfqekJMBIqgOvIOK82Gr6kOmoXn/f5v8aX+2NT/wCgjef9/wBv8aSwk07pkyxCl0LOtWFxaXDNNlgxzux1qkHJHHJpst9dzf626nk/3pCag3N/eP512qLtqc8pJ7F4Mw5zgYqxp+oXNhIxt5NhZdpbGePasrzH/vt+dJvb+8fzo5RcxrictD5J2lS24t3qxPFEYC0Um8IR16sfYVgb2/vH86XzH/vt+dLkDmLkgIJI71ELh0ABO4DoD2qvvb+8350mSepNUo2DmJCwbJPU80gAOKjpc07CuOINAPGD+FNyfU0ZPrQIcCKu2F/PZyb7dyrdOKoUbj6mhxTVmB9Gfs+eKTcXM+n3kmCzAkE9RX1DpE7Xw/d/Jajpx973+lfm5Zaje2E3nWN5c20vTfDKyN+YNbUfj3xhEmyLxXr6J02rqMwH/oVefLA/vOeL07HLPDuVTnvufpEkgc7IcbV6nsKmyF4HJr821+IfjVRhfGHiMD0Gpz//ABVL/wALF8bDp4x8R/8Agzn/APiq7YxktW9f62NVTZ+kg6c0E4r82/8AhYvjb/ocfEn/AINJ/wD4qg/EXxsQQfGPiMg9R/ac/wD8VWocjNL7FcyAiNwR2Bqre6dqFqqzSW03kPwkrIQrH2PQ1s6ddRpeW7upkgR1MiDqyg8gfhmvRPjTq99qEmpXumeM9MuPDM/k/ZdJhvcuFBXC/ZsfuypGSSBwOvOK4lE9mFR3szxZN/RkYH3FaenBZJN8x2qv61O98jxKWjw2ORjrUCW5IZyyhTyBQxqbvfY21vkjTEKg+9H22ZYGVn2hjkg1ixuYpNvX+6KvQReacyxszHpiocUi/atGtpF5DHcL9r3PETyEOCfoa7WVYLm3gVAAzc5A4x61xtrBHFAFKY3dQ3at7RtWitbAIX3NHJjaVzlcHnP6VjNJ6o0jWcmbU2lwW9n5gZssfu5punRBMNGpT3A5qazuVvGD4XZ/CvtW3p8bqxPlKEJ5HcVNu5sqjtqN08ed/qn3J3yMVqR20g5A3D0HarlvaooHyBQfSplj/eBlYnHQetS0YymnsRwRhSpA5/vN/DVlNicuzn1wKI5kLYYAY71OkxZsYUHsfWqUTGRAZB5ygAqCOCe9WUmMeFiXzHPbOKjkMjModB68djT4+uRgnua0UTKSRZhuC3BQg9gamdWK4L8nqR2rPaUtMEiYb+5/u1bTdj97KC304ppHJNWEKqDtQEn1pqgF9vK5pTLuysYximc5xI2SfSqsZXLQHB65xjimSlE5znA5z1pFlRAeenpTsiSPcVC+1JmiIHUldy4GRmqc+GGCCMdMc1akV4iehXsKrOygZHBxk0mXFalOaBHjYvnP15rKmiYKxO1nJyMHBA78VfnucMQqEe57mmR6LFcWcmpPfRQup2+Spy8xz0PoMZP4Vk1c6VaK945+4jJwwII6/SvlCvr24t/KLHI2N2HavkKurBr4vkc+Id7BRRRXacwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB2CyAHcGINVrggsxLfN79DSTriQMFyp647U1oW2MH5A5zXMeheyLFpI0ow5OwcipZbgrlVwR6iqkJOAI+vQ88Vq6Zp5nchmwi/MSegFDS3Yufp0F022dnV3UsT0FdnY2Jtot0q4dhke1Lo2lqm2ZmBUD5T2NX58yv8x4FYVHrZCcrvlRkajIIYS7tgnoKqaOZGkKqULSDOGOAah8TXNvBexwz5l/vqDjaO1bfhDw94f12exMOoXcc6bjdxPwrc/LtP0xThFNXGqq+LoaunT/ZlBQFifv45Cn2NdZoGoiUjL/MOPpWl4m8Hx6da202iQNDZbQZduCRxgdeuWxn0BJ7Vy0IMMwngGyZD86D7r46keuP6VnKKuXSxMZux6Lo32jVLcyWcauBn5JMox29cA98DNJMn8W0rn+FuDUC+ILLVzbyiCRNUVFzcAlArjjgd/lCj61cubqWdVluzvdukh79uaTSWiNPevqrGVLcmFlSMq/PetCEsUBZlZcZ+Xt7Vn3NslxLG3kzKy8ghTtNLbyMsxU4B6DPUU0a6NaGmVeUhSyxe45zVpY9i7uAo7+tUbeaN2wcsM8k+tXvtCDaAuWHQGqOeoFup3tIUUFvTril+45Yn2Ip6q7cHCK3I2054FIUyEKV5GD3pnFN6kckhP8G0ep4qnLIRk7hwO1TXlymzY8geRRhfTHpWDcyyyDEbBcnoKLmVjRt73dchJGCjqBWg0wKjyyD71xMktxBdqXHmAd/SrFrrcivgLhAcOD3qGzSKaOw25TGee9U7qGQK27G09R3NVbTVorolYztf1PerkkrhPmI54JPQe1Fy47mXIqhGjkDMhXKENjaaghX5ySCq4x04+tRat5c6tGzkOB0HFcpLqt9pzx5ZmjDYKnncKybsd1Olzx3O0lt2ZMhlPtXxjX2ZpV/Hf2qyxYXI+56etfGddmE6nDXTi7MKKKK7DnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOqkbyJjkZQ9aR51aMoMFe2Kjlk3HDAc1WCETKAw5PB9K5oq+h1PU2tI0ue7ZWWPbb7grS9lPbNe4fCrwHoerTLFqt9DIcg+QHwX+leUrHfaZZxWxlSMSgEkHIYHoa3NZudLe9tbyOwmtH2hb77NIV3SD/lohzwcY/KiFWcWpQlbXTS/wA3fz7foKU5R+B/13+89c+IngLTfClut1oLSRWMnD2LtuER/vITzz3yT0Fef3rw2mlSXUp+YDKe5q/p/irUNb05tO1G5fUHtebW4kULI6epPc8VxPiu9edRbwtlEzx6VzVHKU2pbv8AIyhGo/ck9/yOJv7prm6klkyzM2SPWt3whqH2e4QodmGz/wDWrKl0u4jiEyrlSM8UmlXL210AhAEpCnI/zjmumLWyOydB8uh9Y+EfEDeINNTT76xE9vKuzOfmhkxwfof61wviuxvNDuDbyL5cySEIMcAZz+WOap+DNWNjParcy7YGYJMyN8w/2gfbr+Fe2654at/EnhuaWeZZZfKza3UfLui8gN75GDis50205LocPOqck3sfPF5q2raX5d1AUe0c4OVwN3cf59a7Dw94nTUbbcqEOP8AWRHkfhWRp50WKDVrHxQu2QxMLQybgvnAHaRjvnA/CsvQrO5sLuVZbe4hhlH7uXHyv9DWNlt/Xoe1Fcy5ktO56QmqymJEZpVUH7pfofYVJLdGeFv3e5l6tjBX/GuMkeSGQSNcOdg5YjtV621yJtg3M0vsMA01HsEkmro6aG7jVSHbCgfMAOaLrUI7ZdzPhgMqG71yV7r3mvsb7yfKp6Z+tNVmuJ4zJMswXlGzwQehp2uc81fc7TRb6S/2zOrxRjoH4wa0Ly43I0cZ8w8ZZegrCVZZY1MzMqnAGOlSTyNHGYwu18DODwRSbRxTLMsiwgKwEgYc/wCNc9qMy7m8piR6Z5NX5LiLKxMrbsdc8YrB1MASSeX94jK4pXuZLRmbc64kLiCWQBu2TUM16iAkN+8Y9uh96xdYtEmm84giVerEcE0+yvo7dFSaAuo7mk9jaJ0UUlxJIkcSMWIyStdHbatNsFrcrlgACx71zljqkUSjk5xhcCpbu4kkKzSALCPl9x7/AI1KKaudc8UcqrkrnH3jzmuX1ixEWowySRloM/NzwR3Htmn2l/Ku0I52Z4yK1oZ4bxjDdRtInTPY0pI3ozaKtpdbNS86w0Se00lyIw0YMkasB3b3wT9TXyRX3zpWpRWfhqXSVibB/wBVx8oG7Jz+tfA1dmFSV7f1uc+IlzW0tb8gooorrOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA2lVnNTrFhdwUj9aZDlecnPaug8OabNeThm/1YOTnoaxtZXeyOta7nT+BZZVhYtZC8LIY1icZ6jtTtVtbxLKSP7K6S5w0W35se/wBOa1bYy6PLHertijjwyFehYVzmreItR1DVpL959sr8Db/WuOTc5+6l5/ov8zNrnnZdN/0X+Zq2mo21rpYEihblV+UDhlYdT/KufWRru5LZ5JzWfLcNISztuPetnw64RvMIXp+daRgk22dUY8uu7Ois7eK4tDDIqkgdR7VjzaHZXcUjzB48EgY/KtlZgjbrcDnqorD1fUHt3uYQ5VXwykj9KV7Dim3poTaNdQWKGGbfK8J+TBx06flx+Fe8fBrxeZNun3uMSn5HJ6H+6B6f418wRSFtsjNyDng813vg/VGtrq2lfPl7gwKnDAd/x61tB2dzmxFFbnu3xS8G2dzANQWNmjBCvEibuSeCMepNeZeIk1GzjsVS7e40u3BVEkXBic9fqOn5V794Y1hdT0S1kuAWE2Y1bbw3pn09K8v+JegvYXsgVWWym+ZHzkZ9D71FWHK1KO35GGGrSpS5GcZLcK0BOeSOR61RjeOMqSwTHTNRxu6TbHxlT09RWja6XLeRpKUyOgz/ABVloezZW5jJugGnLq46ZPpnvV7RrGSUQeTLtYk+ch6KM8Y+tWZ/DpEe/adnYZq/p1s1pCQWAYD9KfMRPVaG7cRTQRKsJYiMYC5zketZkuqGGNkkgl3ngkjNXbK6kWBRI3XhWPp6Uk25i29Qyse3NZyOKcTDkv5JUWMgqB0OO1Q+W8jbXbb6Vo3Mlt54j3fMvVcdagmYSnbGNqkcgjpUoxasY95arnL7iB2rEu7be+EGD25rr2tGZQGYGP1FZ9zpe4brb527p3ociomNpav5hikDkjoccVt3CTLZrBBEWOdzMx71a0yyuTGzTJsZfUVZ8li+2Bz52R8rHPHc0uY0RnWsVxhWY4Vuw7V0VgDDsjRgCOrN/CaPssomTdHhehUDofUVJPpT3l5Eke2NQ33yeOhHIovfc6KaXU63TQ8luILO3muJmIaR1GeB/wDXr4Rr7o8HSXHhXXTbahcGWzlGBMFz24H518L16FCMUro5MSmpeQUUUVuc4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB3nhXQ5dW1KKEW0s0RID+WMnFepX2iW+h2X2SESAYyHcYJ9jXqXwL8KNoWh/briGMPKM/OOdv+Ncr8d/E9hFA2n2UcRm7sBytceaYiNOrHC0tX11+9v9C8VWUGqMNX19evyR4f4u1uWYpZRNhIurA9a51tQmYANgjvjrSXLFpGY5JJzVUfMTlduKcIKKsXBcq0NOGQgq6knPX3rd09zE6yRnKntXLWzNG5DnKntW7YSBSF3ZRqHudlOfQ7qw8q5UjeEYe+K5zxRE+DvXJQ5BX09Kv6ZZJc3UUiysMdR61c16xzdfKco42kdulZvdF+6nocLbhD8rAsWPGD0rpNNdogkbE7R/Ost9Du4GLKrbA3Xtj1rQtoHRowX5Per5l0G6alF6nt3wo8XSWV3Fb3EhSxPyOW+4o9Se2OtegeP9Zvrrw8JPDWlprtvJkSSRsCEHqPU/TpXzVpd5M8M2mPqKWEVyRGZ5D+6Tngv/ALIPJ9q7rQvFOoeHdATw9p2tWNw8zkmSEcxZwCVPoQOPfNVOTnHltfsv8/LyOF4X3/eXp2Ld/wCHrqC1gudStPs8pcCSKTCumegIHUH19q2tPQkYRQUPAGeAa67QtA1HV9KiTxVd2t3K2Q1xHwzIeg9j1rI1jw5L4enCNL5llIcRS9z/ALJ9/wD69ZVKbTb6GtGtFP2TepRliYrlkBw3zAf0qpJZpgtEh3p/Ce4NbcNs7/KoyoAGc0428u0O4BbqD71lY6Lo51ZPIjdCm+M9Qf4fcUxIJryFhDcJERwATgkf/qq9ebpN37vY+eeOvtVIRBeqnJ61LMZIotp90rPHLFlgAVlGOlZ0xmUEqBkHkVt30YVQyH5lGRz19qzpQMiYEbW4xUpmDV2SQo9zCreWEx1C96nltl8veVZHA6qKgiV2O9GCMfvL6/StFTLCv7x2bHORyMUmwRHaQTPtKNviPQnufSrf9nXK3SzMkSleOma3rCdWtyqRgRbeoHQe1SxIoBO5mfPQjigtGYls6jcS27rnrWxY2scDx3EaKzgg5cZDe+KfEI12hiPbHNXLYZkwOT/DnpVA5aF2Fbe+u83MKlGbnHH4j0r88K/ReCMkDkD6Cvzortw2zOee4UUUV1EBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6G/EXWItG8OTeW/lFU2pt45r418UapJf3000zmQsepPJr0X4s+LLi+lMHmSKMYZWPQ/SvILmQNnOOa8TCU5SlKvU+KRlhqermyjK+WI5x7dqRThuOtDAHODgUbOeg9q9JHcPDY5PUVasrko+0j5T39Ko8g8nNSRMM8ng+lDKV1sdnoeoNb3Cbz8r8E+ldHqMiuMGUDJ7nrXm9rc+Wdu7I9a3obx7i1KgbmXnNZyWh0U7Ts2dtMjNZbI8tHsGazY7GKa2QAklWxkHkVc8NA3mnrmU7l4Kk9vSpb0xWrssMW0kjOe9TJ20NI6SsYd9abZD5IBwOc9q9Z+Fngbw74m8JzXtzp32bVbaQob1HJ3gAHkZx3NeX3soLoEH1rqPBviXWNBlh/s2fEO7L25HySeoP4U6c+VNdzarSlUhyrQ+mNKW1hhjjWIGQDBPpUPiS7tl0iVXTeudqhl4DdsV5Ne+OtV1JFjSOCyLdXjJLH8at295f3MMaz3cs8a8qsjcfX61E60px5Weasvs+eb1NuLapwOU9RzxStwOJPvHsOhrOS7YACJQRnDZ6ir8Icrndj1HaoOmUbFTUbUyLv2sxUdemT61hTCSKQeYuc9CO31rqpGfbhjkdmrIvoeC247qlmbRhXcsTxEFinqSOhqhZIrSFFdHRjx/WrGoupyN3AHIx0rJhZYpQ44APOe9StzJo2WjgV/L3MGHKn0rThiVUVkYyRL95e4Pr+P9KptCrCJ0AwSOver2FhIwxcjqF6EUhJGpYXMR+42I8fdNXY18wY3YUfwetULSKEqCMKSe/atWJljAwBk9xStYGrbDI4Y0kUI2HYnK/wB0e9aGGBGwYx6fzqNNpkUMcVpRRKvfgjketUK9iaGRzGMEA+1fnPX6KNEsWTGSufevzrrtwr3MZ26BRRRXWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAez/F28tZdRBgG2UcNjvXmUk4JOcVr+JtQN5fyOWzzXPyNu6jrXBhaXs6aiworliWUwy9amEfcNWajFWyCcircdyQfnrdxOhS7k7RkAnGaj2kZL4UE8VYimWTq1SlEbqyn61N2nqaJ3KJBB4PWtjQbry513fd6EetUZYgOMg/Ski/dkEnGOc073HG6dz0fw/KlrespyIpOhHY9a2NaRWtvOT5ivOT6Vx1jcefp8ciPkrwcVuRXD3ViY2JIx+Vc84s6oq7uZjsZryFEYBpOMk8AV1+nWccSrGsh3KPvelcPdx+TqFsM4wwrudKm8yQcDAA6d6l2sd6u4qx01lYu3DupQ9BjnPtXQWiLCp+Ztp4I9PesTTZhlVjbdjp7VtLdoZEjcHcw4wKzZlKLejL0GVVVjKOo7+tXEnUrtIbA9KhhjUneh2noVPSp1J/i2++2lc55IiluHIIjQ7Ryc1GZfNiIOQR7U68cRqHCnr2NVTOd/BwWHSi5k0ZWrQjaXAGPpXLXjJuIy2D+ldtdoZY238nHI7CuV1KHEpCEc+tJOzMpRNDRJN0KrM28L93Fb6hA4QgRk4IX1rn9Fh8uQyLGd6jHPQV0DSCZV8wAlP4j1xQ3qZ2L9uUWRUkA2t3q4HMUgRQGXPyk96z45FZduMMPWrDOriNQCH9umKm4jVtwZDuwCfStWJsIOBWZFJGFURjd7CpxIxPBwR27VaJZbumwmehFfnZX6CXcpEeO/8q/PuuzCdTOYUUUV2GYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBs3THfk1VdiQc9atXByeD+FVBnkcVhE0Q3knrSM2BzkmhkYngmmqgDckmrQxw3AAqDUsU0i4zzUqAehzUnlr9KlyKSCO6A4bIqXzEcdvxqo8Xvx6mo1Qg4VsfWhJFJs6bw7P8AO8WdoP5V1VjciBsZGCMH3rz7S5niuo9x74z611hJXDdQeQawqqzud1D3kXNVcG7jZsgBhg1s2Vw6Mki4UDqa5q6lWUKW4C4xWzYygxqrZ2t7d6wbtoerSh7p22nXixsmASoGRzwa6PS5nmnDFCqEcbq4qxYCNQmBgjk812WkOUt8E7lrNsma0OngcgYOAR1pj6hZxSpDJcJHNIflRuN9Q28iMgOT+NE9nb3DK80MblTuViOQfaobscllfUllnWSMhMq46gjqKx57kK2d2cHB5q/dSsvQYI/WsO7kTzd7KF3D9aSkc8lY2Y5BLGCDzjketULu2D7srlwcil0yVSw2ONwHK1ouu9AyoVHTBFDepjIhtI3WEBQBjj1zVmHB5YfUelT2cKsvGce1WJIMdx7GlcgqFTGeBlT0NXLEOxGzqTzn0qDduiZSRletWdNJjIZiRnoRzTRDRrJboBlsr34qNvMQkK2cetTCTC8c55qOUhlO5tp9K0JtYo3NywDAthulfCNfb2pSPErF8Mnb1FfENdmE6kVVsFFFFdhiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAasp+Y9KYgz0prMS1Pj/SsdjZChMn0FKIV3c/pUyj2yKXYAeDj3qbl2E2jHB/+tTUYFvm4qVQPrTkCrknmlcdhvUcdKryx8n+lTkHJ2//AKqQrhSTmmmFiGIlZFJ6jvW1b3j8KWO30NYxQ5z2q5bNyh98VNTU7MJKzcToUBmZEX736V0ukBoEAaLeVOTxWLo0TOyFRksfyrt9MtWBUg84weK45Ox6ynaNjTsYEZRJGoXcOTW3ZiRW/dj5u3pWQrtDMqSD93jjFbFnJEjLksD2rFu+qI6G3bnagZoyCeTVsMCvPBFVoJQ6/ez68VJKVC9RUN2OaSMzVrlol/dqC/Y9a5+a+JAWZcMDn2rR1CRllyOVrHnjV2LyFh6YFJM56iNrTZkUI8KbiTz7V01pL52VZStc34dPmkqoyFGM4xmumsODtcjjvVXOdllIpIH3jlTVyRd8OQv4Ui9MEhlpHJhAwTtPQiggqwQq24Nx2q7p0YwUwAB0zVaJWYsVGQOoNXrORR/DgYplWJ5Ssa/Px7iqMzvznle2KuTygjPUCsu5nycKQDVJiUTI1iYlWUg/jXxZX2D4muTHCQHGT1r4+ruwevMZV1ZIKKKK7TmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKALpbBG6pojx+NVhtLAnmpk4ztIxWTRsi2p7g4Bp4znsahXoOakUnPXB9KzLL9jZi5DM9xHbxKMtI/JA9h3NQlRnCnI7HpUAbPU5x0qTcDx1HpSYxcdemKjHfBqQc8Hp6UYyD60IZBjDVPZ8y7TnrUQTB5p0Xyyq3PWm9S6cuWSZ32gRqADz6/Su40xTLEMggdq4jw++VVcAZFdxpbsXVM4HeuKZ6zdzSksjKoDNkrVmwgkRcbsgdiKuWETSzKjyLGG48zGdtXNSsf7Pn8lLqO7IGTJH0NczutQU9bCRShWBkIGOOKfdbmXcgyMYqmkgcAAAE+tWPMCrjr61EhyiY9zE2Tg5qGIAfI38XStiWAPHgfgazbu1YFd4JPUEdqSfcwnEvWkbOFWA+Tjhn710Gl2qxna8hY9ye9cxE8kBBJ6Dv3FbWnanGcLEpPrntVxOedPqdWkcWzaV4x1pDEoBU/Mh457VDBKTDnOWPrUiStFxOdwJz05qjDlIYgbWUI3I/hbtU80Z3Bk4B59qbccY4G0+tVmuNigLk+g7Uh7llcnJ4+tZepRBWLb8Mf4fWpJbhgxHKk1n3BLE5J3dsmhs0iupz+rQeeW3KRXyPX2XcRHDFuuOlfGld+A+18v1ObFdAooor0DkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAJs4PrUyHI7ZquMipFbAqGi0y4pzTwwHHNVlbnjvVhevXIrNo0TJ4gWx2XFP6HAPA9ahBABHb2p6c/QVLGSp7dKeOnFMB68/WnLg96RSADk8U4Jk5FOVOgNSrGM4pXKSOp8KOxZQx6V6LYEbRt6+hrzDQZDE4A6E13unXI2qQxrkrau56UG2kddbuWAzU4JC7VwFHpWVbT5Ue9WDchBuJ49K52jaKuWT8soDDr6VbALKD+p71npMJACOnatCIllAzxWctNDRqyJUUDjNV7jHmAdR6itBUO3OBnGM1mXitG/qp61Ji7MsrBG6qHwwPQ1etII4DuUCqmnDMWe1acGB0GaaOSoXUkwuVOR3p4uSrDJPHtUCsuMCkZgH+fpjjFXczRZkcTYIyVP5U+NVQ/MN3p7UQBAOD7+wp5YDjt6DvQFhkgTBHBasueLgFgBg8VqOkcaNgfMTkn3qjcED3BqSkZs/OWccV8W19oXzYJO7qMYFfF9ejl/2vl+pzYtfCFFFFeicYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBOMYwTTMnPtQnJ5p5IxxUlrUI3IPfFWY5MCqwOKcpwOKTRSLisOO9WEGeTxVKMnI64q6jcelZSLRIOD609SfT6CowTnpU0akknNIpE8KgnmrSIMAAVBGOO9TxZDeorOTNUjZ02IV0dk5jxk8Vz2muODnmtmJhxjpXNPc76Z0tpegYBOauPKJUx3rlo5irdeK07e4OAM/nWMlodUV1N60O1QAxwDW3ZNucA1zVtcDbnPStzT5lJUg5rBlTWh1EQGwZxmql4iMORTopxs64qKaZWBGaybORrUis3VUYZxjtWjC6jGOQwrnLmcQo7g9Ks6ZerPb/K3I5rWOuplNXN04GAGpFJ3ZAz7VnSyOVDKx4NWbZ2HzMeT2HaqM0jViYDkgg9frUoYAkkHHrWf5j5BB4PWrHn/LzQTYWeYF1yapXdxgegpZHGcjGBWbfTbj8ucmpuaJEckokuAPevjivsaziIbLYNfHNejl/wBr5fqcuM+yFFFFekcIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA7BFOHSnYwcNmpY48kZ71LZqodiI+3SnqPT8qtfZQw4FL9mKio50VysiTtirkYJHGMVCsRBz6VZgGBg8VEmWkORcYwPwqxF168+lIqcHFOQGoZaRZXOKmjPTjIqKPpk1Mn3hzke1QzRGpZcY7VqxyZGO9ZNrkAGrvmYxziueR20y8rnODkGtC3c5U1hrJhu9aEEoC9eBWbR1o6GJwVzkVp6fPtZQWxXLR3jL1P4VJFqirIPmArJxNVHmPQo7obcZFQvd4JAxx3rn7S+3x7h0qVmLhCj5DdvSsHHU55RUS5LcCYOrYwajtFNuxZGPHOB39qS0iypz0q3EnzjB46U07bHPNXL0d2Wj4PFWbadywOelZot3i3becjip7U7M7jyarm7GaN2Ob5frUrygrjNZMLkHOSfxqTeCw+YUmybElxNk4zzUKAMuTmoWb5+ScelTRvh+OlLcZPbABu+a+Ma+z0kAORXxhXp5d9r5fqcWL6BRRRXpHGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cecal ulcer with bleeding visible vessel; (B) Injection therapy of cecal ulcer with epinephrine 1:10,000 dilution; (C) Combination therapy of cecal ulcer with epinephrine injection followed by hemoclipping x 2. The dark pigmented area to the right of the hemoclips is due to India ink injection for mucosal tattooing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sammy Saab, MD and Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10915=[""].join("\n");
var outline_f10_42_10915=null;
var title_f10_42_10916="Carteolol (ophthalmic): Patient drug information";
var content_f10_42_10916=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carteolol (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/31/1525?source=see_link\">",
"     see \"Carteolol (ophthalmic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701730",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carteolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, slow heartbeat without a working pacemaker, or wheezing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11553 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-4BCC47CC64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10916=[""].join("\n");
var outline_f10_42_10916=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030263\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030262\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030267\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030268\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030270\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030265\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030266\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030271\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030272\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/31/1525?source=related_link\">",
"      Carteolol (ophthalmic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10917="Laparoscopic ligation of the superior hemorrhoidal artery";
var content_f10_42_10917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Laparoscopic ligation of the superior hemorrhoidal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pictures shows the ligation of the proximal end of the superior hemorrhoidal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10917=[""].join("\n");
var outline_f10_42_10917=null;
var title_f10_42_10918="Abacavir, lamivudine, and zidovudine: Drug information";
var content_f10_42_10918=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abacavir, lamivudine, and zidovudine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/34/42533?source=see_link\">",
"    see \"Abacavir, lamivudine, and zidovudine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/43/6839?source=see_link\">",
"    see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trizivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7792786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trizivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F128888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F128874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Adolescents &ge;40 kg and Adults: One tablet twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for patients &lt;40 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Adults &ge;50 kg: One tablet twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for patients &lt;50 kg.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F128883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/43/6839?source=see_link\">",
"      see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Adolescents &ge;40 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F128875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F128876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F554132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F128854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Trizivir&reg;: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089807.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089807.pdf",
"     </a>",
"     , must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F128857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F128856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection (either alone or in combination with other antiretroviral agents) in patients whose regimen would otherwise contain the components of Trizivir&reg;",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F128886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatal hypersensitivity reactions have occurred in patients taking abacavir (in Trizivir&reg;). If Trizivir&reg; is to be restarted following an interruption in therapy, first evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or if hypersensitivity cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The following information is based on CNA3005 study data concerning effects noted in patients receiving abacavir, lamivudine, and zidovudine. See individual agents for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (13%), malaise (12%), fatigue (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever/chills (6%), depression (6%), anxiety (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (2% grade 3-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea and vomiting (10%), diarrhea (7%), amylase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nose/throat infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity (2% to 9% based on abacavir component), viral infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other (frequency unknown): Pancreatitis, GGT increased, fat redistribution, immune reconstitution syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F128860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; hepatic impairment. Do not rechallenge patients who have experienced hypersensitivity to abacavir regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): End-stage renal disease (ESRD); ANC &lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; hemoglobin &lt;7.5 g/dL or 4.65 mmol/L",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F128844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia);",
"     </b>",
"     use with caution in patients with bone marrow compromise. Canadian labeling contraindicates use if ANC &lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or if hemoglobin &lt;7.5 g/dL (4.65 mmol/L).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Fatal hypersensitivity reactions have occurred in patients taking abacavir (in Trizivir&reg;).",
"     </b>",
"     Patients testing positive for the presence of the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele are at an increased risk for hypersensitivity reactions. Screening for",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele status is recommended prior to initiating abacavir-containing therapy or reinitiating therapy in patients of unknown status, including patients who previously tolerated abacavir therapy. Trizivir&reg; should",
"     <b>",
"      not",
"     </b>",
"     be used in patients testing positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele. Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record (DHHS, 2013). Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks Patients exhibiting symptoms of fever, skin rash, fatigue, respiratory symptoms (eg, pharyngitis, dyspnea, cough) and/or GI symptoms (eg, abdominal pain, nausea, vomiting, diarrhea) should discontinue therapy immediately and call for medical attention. Trizivir&reg; should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible and regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status. Trizivir&reg; SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. Fatal hypersensitivity reactions have occurred following the reintroduction of abacavir in patients whose therapy was interrupted (eg, interruption in drug supply, temporary discontinuation while treating other conditions). Reactions occurred within hours. In some cases, signs of hypersensitivity may have been previously present, but attributed to other medical conditions (eg, acute onset respiratory diseases, gastroenteritis, reactions to other medications). If Trizivir&reg; is to be restarted following an interruption in therapy, first evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis/hepatomegaly:",
"     <b>",
"      [U.S Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;",
"     </b>",
"     use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy:",
"     <b>",
"      [U.S. Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy and myositis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis B:",
"     <b>",
"      [U.S. Boxed Warning]: Exacerbation of hepatitis B has been reported with discontinuation of lamivudine in coinfected HIV/HBV patients;",
"     </b>",
"     monitor hepatic function closely for several months after discontinuing Trizivir&reg; in coinfected patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary heart disease: Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: This combination should only be used as part of a multidrug regimen for which the individual components are indicated.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Trizivir&reg;, as a fixed-dose combination tablet, should not be used  in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Concomitant use of other abacavir, lamivudine, or zidovudine-containing products with the fixed dose combination product should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Emtricitabine: Concomitant use of emtricitabine-containing products should be avoided; cross-resistance may develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HBV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adolescents and Adults &lt;40 kg: Trizivir&reg;, as a fixed-dose combination tablet, should not be used in patients &lt;40 kg or those requiring dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F128848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7794626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol may increase the risk of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F128879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F128864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F128865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F128862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trizivir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-150-300 mg (60): $1931.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5564474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose, CBC with differential, serum creatine kinase, CD4 count, HIV RNA plasma levels, bilirubin, serum transaminases, triglycerides, serum amylase;",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status; signs and symptoms of hypersensitivity, particularly in patients untested for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele; signs and symptoms of pancreatitis; observe for appearance of opportunistic infections",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tricivir (AR, CN);",
"     </li>",
"     <li>",
"      Trivudin (AR);",
"     </li>",
"     <li>",
"      Trizivir (AT, AU, BE, BG, CH, CL, CO, CR, CZ, DE, DK, FI, FR, GB, GR, HK, HN, IE, IL, IT, MX, NL, NO, PE, PT, RU, SE, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F128843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The combination of abacavir, lamivudine, and zidovudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F128859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability studies of Trizivir&reg; show no difference in AUC or C",
"     <sub>",
"      max",
"     </sub>",
"     when compared to abacavir, lamivudine, and zidovudine given together as individual agents. See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas A, Nolan D, and Mallal S, &ldquo;HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2007, 59(4):591-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10918/abstract-text/17317695/pubmed\" id=\"17317695\" target=\"_blank\">",
"        17317695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8700 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10918=[""].join("\n");
var outline_f10_42_10918=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708609\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128871\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7792786\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128888\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128874\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128883\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128875\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128876\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554132\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128854\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128840\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874273\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128857\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128856\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128886\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128860\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128844\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298626\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7794626\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128850\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128863\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128879\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128864\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128865\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128862\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5564474\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539807\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128843\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128859\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/34/42533?source=related_link\">",
"      Abacavir, lamivudine, and zidovudine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/43/6839?source=related_link\">",
"      Abacavir, lamivudine, and zidovudine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10919="Prenatal diagnosis and management of bronchopulmonary sequestration";
var content_f10_42_10919=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal diagnosis and management of bronchopulmonary sequestration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Dorothy I Bulas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Alexia Egloff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10919/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/42/10919/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31928889\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary sequestration (BPS) is a congenital anomaly consisting of a nonfunctioning mass of lung tissue that lacks normal communication with the tracheobronchial tree and receives its blood supply from the systemic (rather than the pulmonary) circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/1\">",
"     1",
"    </a>",
"    ]. The feeding vessel most commonly originates from the aorta, although other origins, such as the splenic artery or gastric artery, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/2\">",
"     2",
"    </a>",
"    ]. BPS accounts for only 0.15 to 6.4 percent of congenital lung malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BPS is classified anatomically as intralobar or extralobar:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In intralobar pulmonary sequestration (ILS, also known as intrapulmonary sequestration), the mass is located within the normal lung and is covered by the visceral pleura of the lung. Postnatally, ILS accounts for about 75 percent of BPS and is almost always located in the lower lobes, most commonly in the left medial or posterior segment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Venous drainage is usually via the pulmonary vein to the left atrium, although connections to the vena cava, azygous vein, or right atrium also occur.",
"     </li>",
"     <li>",
"      In extralobar pulmonary sequestration (ELS, also known as extrapulmonary sequestration), the mass is located outside the normal lung and has its own visceral pleura. Postnatally, about 25 percent of BPS is extralobar [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/6\">",
"       6",
"      </a>",
"      ]. An extralobar lesion can occur between the neck and diaphragm, within the diaphragm, or infradiaphragmatically, where it can mimic a suprarenal neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ]. The most common location is between the left lower lobe and hemidiaphragm [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/5\">",
"       5",
"      </a>",
"      ]. Most ELS drains to the systemic circulation through the azygous or hemiazygous vein or vena cava [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/3\">",
"       3",
"      </a>",
"      ]. ELS is more likely than ILS to be associated with anomalies, including congenital diaphragmatic hernia or eventration, cardiac defects, and foregut anomalies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hybrid combinations of congenital pulmonary airway malformation (CPAM) and BPS are relatively common, and have connections with both the pulmonary and systemic arterial supply.",
"   </p>",
"   <p>",
"    This topic will discuss prenatal diagnosis and management of BPS. The epidemiology, pathology, and pathogenesis of BPS, and the neonate's clinical presentation, evaluation, treatment, and outcome are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31929161\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928895\">",
"    <span class=\"h2\">",
"     Imaging the normal fetal lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=see_link\">",
"     \"Prenatal diagnosis and management of congenital pulmonary airway malformation\"",
"    </a>",
"    .) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63320 \" href=\"UTD.htm?43/14/44257\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74495 \" href=\"UTD.htm?7/54/8035\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928901\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of BPS is suggested by the presence of a solid appearing, triangular, echogenic mass, which is often located in the lower hemithorax adjacent to the diaphragm. Hybrid lesions have cystic and solid components. BPS is usually unilateral, but bilateral cases have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A characteristic feature is visualization of a systemic artery to the fetal lung lesion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51114 \" href=\"UTD.htm?31/5/31829\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50003 \" href=\"UTD.htm?16/27/16822\">",
"     image 4",
"    </a>",
"    ). Color and power Doppler assessments are critical for identification of the systemic vascular supply, which typically arises from the abdominal or thoracic aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/9\">",
"     9",
"    </a>",
"    ]. Even with thorough assessment, however, the vascular supply may not be visualized prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When evaluating the fetus with a thoracic lesion, it is important to also assess for midline shift, pleural effusions and other signs of hydrops, and associated abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928907\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) imaging typically reveals a hyperintense T2w mass in the lower lobe (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51114 \" href=\"UTD.htm?31/5/31829\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50003 \" href=\"UTD.htm?16/27/16822\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,9,11\">",
"     4,9,11",
"    </a>",
"    ]. The feeding vessel may be a low signal line coursing from the aorta into the mass. MR does not always demonstrate the abnormal vessels, but is helpful in delineating the mass and its location (chest, diaphragm, or infradiaphragmatic), evaluating the contralateral lung, and assessing for other congenital abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928913\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prenatal differential diagnosis of BPS includes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928919\">",
"    <span class=\"h3\">",
"     Congenital pulmonary airway malformation (CPAM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both microcystic congenital pulmonary airway malformation (CPAM) and BPS appear solid and homogeneous on ultrasound and MR imaging. Identification of a systemic arterial feeder helps differentiate BPS from microcystic CPAM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=see_link\">",
"     \"Prenatal diagnosis and management of congenital pulmonary airway malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928925\">",
"    <span class=\"h3\">",
"     Congenital lobar emphysema (CLE)/ congenital lobar overinflation (CLO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographic features of",
"    <span class=\"nowrap\">",
"     CLE/CLO",
"    </span>",
"    include a bright echogenic lung with normal pulmonary blood flow; cystic lesions may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/12\">",
"     12",
"    </a>",
"    ]. Prenatally, this diagnosis can be difficult to differentiate from microcystic CPAM and BPS. The presence of normal pulmonary vascularity excludes BPS and microcystic CPAM, but this can be difficult to demonstrate. The diagnosis is confirmed postnatally by computed tomography, which shows emphysematous alveoli in CLE and distorted lung tissue in microcystic CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=see_link\">",
"     \"Congenital lobar emphysema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928931\">",
"    <span class=\"h3\">",
"     Congenital diaphragmatic hernia (CDH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herniated bowel loops in the hemithorax can mimic a multicystic, heterogeneous lung mass. Mediastinal and cardiac deviation may be the only hint that a CDH is present in the relatively rare instances where the stomach remains infradiaphragmatic. When the stomach is herniated into the hemithorax, nonvisualization of stomach bubble within the abdomen is helpful for making the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. Peristalsis of bowel loops in the thorax can sometimes be seen by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ]. Deviation of the umbilical portion of the portal vein suggests liver herniation into the thorax. Direct visualization of hepatic vessels extending into the chest confirms liver in the thoracic cavity. MR is particularly useful in assessing the amount of liver herniation and delineation of small and large meconium filled bowel in the chest. Meconium is dark on T2 and bright on T1, while liver is high on T2w and intermediate on T2w, thus easily differentiated from adjacent lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42169?source=see_link\">",
"     \"Congenital diaphragmatic hernia: Prenatal diagnosis and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928937\">",
"    <span class=\"h3\">",
"     Neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastoma, as well as other intraabdominal masses, such as mesoblastic nephroma, can mimic an infradiaphragmatic BPS. Thorough examination to assess origin can help differentiate between these lesions: mesoblastic nephroma arises from the kidney, is most common on the right side, and can be cystic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ], whereas BPS is more common on the left and appears solid.",
"   </p>",
"   <p>",
"    Neuroblastoma is often diagnosed in the third trimester and tends to grow over time, while BPS is more often identified in the second trimester and tends to regress over time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32456?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of echogenic masses and calcification in the fetal abdomen\", section on 'Neuroblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928943\">",
"    <span class=\"h3\">",
"     Adrenal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to BPS, the key to diagnosis of adrenal hemorrhage is the change in appearance over time. The initial appearance is that of an echogenic and solid-appearing lesion without internal flow. Subsequently, a hypoechoic central region develops, and then a more cystic appearance and a decrease in size are observed. Dystrophic calcifications may develop. On MR, hemosiderin may be present in a hemorrhage. BPS has a systemic feeding vessel and is diagnosed in the second trimester whereas adrenal hemorrhage typically occurs in the third trimester and has no feeding vessel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928949\">",
"    <span class=\"h2\">",
"     Prenatal course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large thoracic mass lesions in the fetus either regress in absolute size or size relative to the thorax and thus cause minimal morbidity, or they enlarge, often resulting in mediastinal shift and hydrops.",
"   </p>",
"   <p>",
"    BPS is usually a small lesion, and decreases in size in late gestation in about 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,9,15\">",
"     4,9,15",
"    </a>",
"    ]. However, masses that appeared to resolve in utero are typically found on postnatal computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The apparent resolution has been attributed to decompression into the normal lung, outgrowth of the systemic circulation, or torsion around vascular pedicle resulting in vascular and lymphatic obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ]. As these lesions regress, they become more difficult to visualize on ultrasound. On MR, the lesions may appear of lower signal intensity to lung on T2w as they regress.",
"   </p>",
"   <p>",
"    When BPS presents as a large intrathoracic mass, the fetus is at risk of compression of the heart, thoracic venous structures, and esophagus resulting in hydrops and polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,15,18\">",
"     4,15,18",
"    </a>",
"    ]. Hydrops can also result from shunting when there is a systemic arterial feeder and the mass drains via the pulmonary circulation. However, large lesions with mediastinal shift, dextroposition, or cardiac compression do not always cause hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognosis is typically very good in the absence of hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Survival falls to 20 to 30 percent for fetuses with pleural effusion or polyhydramnios, but these cases are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 41 fetuses with extralobar pulmonary sequestration, 28 dramatically regressed on serial prenatal sonography, were asymptomatic after birth, and were only detectable by imaging studies postnatally (no resection performed ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/15\">",
"     15",
"    </a>",
"    ]. Of the remaining 13 fetuses, 2 underwent elective abortion, 1 hydropic fetus died, and 3 fetuses developed tension hydrothorax with secondary hydrops that was successfully treated by fetal thoracenteses or thoracoamniotic shunting followed by postnatal resection. Seven fetuses were symptomatic at birth and underwent resection of the lung lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928955\">",
"    <span class=\"h2\">",
"     Prenatal management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a lung mass is first identified, thorough assessment of the entire fetus is important to look for additional anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. Intralobar sequestration is not associated with an increased risk of additional anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. Extralobar BPS is associated with anomalies in up to two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/19\">",
"     19",
"    </a>",
"    ]. These anomalies include chest wall and vertebral anomalies hindgut duplications, diaphragmatic hernia, congenital heart disease, and renal and intracranial abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4,14\">",
"     4,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of chromosomal abnormalities is not increased above baseline in fetuses with BPS alone; this should be considered when weighing the risks and benefits of invasive prenatal testing to determine the fetal karyotype. The risk of chromosomal abnormalities is increased in fetuses with additional anomalies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonimmune hydrops. Karyotype analysis is recommended prior to initiating fetal therapy, and risk of these procedures and the increased risk of chromosomal abnormality in hydropic fetuses. However, fetal intervention is rarely needed.",
"   </p>",
"   <p>",
"    Parents should be counseled about the possible course of the BPS during pregnancy (likely decrease in size, but may increase, potential for hydrops), the potential need for and the options for prenatal intervention, the differential diagnosis of prenatally suspected BPS, and postnatal issues (clinical manifestations, postnatal evaluation, postnatal management, potential complications, prognosis of associated anomalies, and range of outcomes). At initial presentation in the early midtrimester, it is difficult to accurately predict what the outcome will be for an individual fetus, but some predictions are possible, eg, a large BPS with hydrops in the second trimester is likely to do poorly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should have serial prenatal follow-up examinations to assess change in size of the lung mass and development of hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"     4",
"    </a>",
"    ]. The frequency depends on the size of the lesion; larger lesions should be followed more closely.",
"   </p>",
"   <p>",
"    Although rare, the presence of hydrops is a sign of impending fetal demise and an indication for fetal intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/11\">",
"     11",
"    </a>",
"    ]. This recommendation is based on results from small case series showing higher survival rates if hydrops resolves; no randomized trials have compared management approaches. A systematic review found that survival rates were significantly higher among hydropic fetuses who underwent prenatal drainage or resection than in hydropic controls who did not have these interventions (OR 9, 95% CI 3-101) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because hydrops is uncommon, fetal intervention is rarely required and is warranted only in cases where the fetus is severely compromised and remote from term. For fetuses greater than 32 to 34 weeks of age, early delivery with immediate postnatal resection is a reasonable option [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/15\">",
"     15",
"    </a>",
"    ]. Ex utero intrapartum therapy (EXIT) has been used to stabilize fetuses with large lesions expected to have difficulty breathing at delivery (See",
"    <a class=\"local\" href=\"#H31928961\">",
"     'Delivery'",
"    </a>",
"    below.) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For gestations between 20 and 32 weeks, several interventions with the goal of improving fetal hemodynamics and preventing lung hypoplasia have been described and appear to improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/17\">",
"     17",
"    </a>",
"    ]. These interventions should only be undertaken at centers experienced in fetal surgery. Prenatal intervention requires extensive counseling to the parents on the potential risks versus benefits of surgery.",
"   </p>",
"   <p>",
"    A macrocyst within BPS suggests a hybrid lesion (macrocystic CPAM and BPS). In these cases, a maternal course of antenatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (two doses of 12 mg intramuscularly 24 hours apart) and cyst drainage are options, as with CPAM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=see_link\">",
"     \"Prenatal diagnosis and management of congenital pulmonary airway malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the BPS is solid with a large pleural effusion, thoracentesis to prevent pulmonary hypoplasia is possible, but rapid reaccumulation of fluid limits its usefulness. It can be used as a temporizing maneuver to provide prognostic information about the possible result from placement of a thoracoamniotic shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/15,20,22,23\">",
"     15,20,22,23",
"    </a>",
"    ]. The fluid should be sent for cell count to exclude an infectious etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/23\">",
"     23",
"    </a>",
"    ]. Complications of shunts include displacement or malfunction of the catheter, thrombus occlusion of the catheter, fatal fetal hemorrhage, procedure related abruptio placentae, premature rupture of membranes, and preterm labor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/22\">",
"     22",
"    </a>",
"    ]. There is also a risk of trauma to the fetal chest wall, especially if the procedure is performed before 20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned series with four hydropic fetuses with extralobar sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/15\">",
"     15",
"    </a>",
"    ], hydrops resolved after serial thoracenteses in one fetus and after thoracoamniotic shunt placement in two fetuses; all three neonates underwent resection of the lesion after delivery in the mid to late third trimester. The fourth hydropic fetus was not treated in utero and died of pulmonary hypoplasia after a prolonged neonatal course.",
"   </p>",
"   <p>",
"    A review of 294 cases of fetal lung masses included 23 with pulmonary sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/18\">",
"     18",
"    </a>",
"    ]. Among these, three developed hydrops and all were successfully treated in utero.",
"   </p>",
"   <p>",
"    Percutaneous laser ablation of the feeding vessel has been reported to decrease tumor size, but experience is limited and the optimal technique is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In a literature review of laser ablation of BPS, complete resolution of fetal hydrops was observed in six of eight cases and seven fetuses survived [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/27\">",
"     27",
"    </a>",
"    ]. In-utero open resection has been successfully performed to salvage the hydropic fetus remote from term [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/28\">",
"     28",
"    </a>",
"    ]. This infant had good pulmonary function and development at 20 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928961\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery planning should be in conjunction with the pediatric staff (neonatology, pediatric surgery). If the lung mass has resolved or is small with no mediastinal shift or hydrops, BPS itself is not an indication for early delivery or cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/23\">",
"     23",
"    </a>",
"    ]. Neonatal respiratory problems would be unlikely.",
"   </p>",
"   <p>",
"    For fetuses with large masses that cause mediastinal shift",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydrops, delivery should be planned for a tertiary care center with an intensive care nursery capable of resuscitation of a neonate with respiratory difficulties, including capability of extracorporeal membrane oxygenation (ECMO), and with pediatric surgeons experienced in care of these infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/22,29\">",
"     22,29",
"    </a>",
"    ]. If hydrops develops after 32 weeks of gestation, early delivery is recommended, possibly with the use of ex-utero intrapartum therapy (EXIT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10919/abstract/29\">",
"     29",
"    </a>",
"    ]. In EXIT, the fetus is partially delivered and intubated without clamping the umbilical cord. Uteroplacental blood flow and gas exchange are maintained by using inhalational agents to provide uterine relaxation and amnioinfusion to maintain uterine volume. This provides time for initiating extracorporeal membrane circulation to stabilize the infant, thus creating a controlled situation before resection of BPS in another operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928967\">",
"    <span class=\"h2\">",
"     Postnatal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal presentation, neonatal evaluation and care, complications, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31928973\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchopulmonary sequestration (BPS) typically has the appearance of a solid homogeneous mass with a systemic feeding vessel. It can be supradiaphragmatic, diaphragmatic, or infradiaphragmatic. When supradiaphragmatic, the most common location is the left basal chest. When infradiaphragmatic, it most likely occurs in the left suprarenal area. A hybrid of BPS and congenital pulmonary airway malformation (CPAM) should be suspected if ultrasound shows a mass with both solid and cystic components and a systemic feeding vessel. (See",
"      <a class=\"local\" href=\"#H31928889\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31928901\">",
"       'Ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of thoracic BPS included CPAM, congenital lobar emphysema, and congenital diaphragmatic hernia. When intraabdominal, BPS can mimic adrenal hemorrhage, neuroblastoma and mesoblastic nephroma. (See",
"      <a class=\"local\" href=\"#H31928913\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      BPS usually decreases in size in late pregnancy and prognosis is typically very good in the absence of hydrops. Large lesions can cause mediastinal shift and may be associated with hydrops, which has a poor prognosis. (See",
"      <a class=\"local\" href=\"#H31928949\">",
"       'Prenatal course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial evaluation should include assessment for other congenital anomalies. The incidence of chromosomal abnormalities is not increased above baseline in fetuses with BPS alone. Serial prenatal ultrasound examinations should be done to assess change in size of the lung mass and development of hydrops, although this is rare. (See",
"      <a class=\"local\" href=\"#H31928949\">",
"       'Prenatal course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31928955\">",
"       'Prenatal management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/1\">",
"      PRYCE DM. Lower accessory pulmonary artery with intralobar sequestration of lung; a report of seven cases. J Pathol Bacteriol 1946; 58:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/2\">",
"      Gomez L, Robert JA, Sepulveda W. Fetal retroperitoneal pulmonary sequestration with an atypical vascular pattern. Prenat Diagn 2009; 29:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/3\">",
"      Vijayaraghavan SB, Rao PS, Selvarasu CD, Rao TM. Prenatal sonographic features of intralobar bronchopulmonary sequestration. J Ultrasound Med 2003; 22:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/4\">",
"      Azizkhan RG, Crombleholme TM. Congenital cystic lung disease: contemporary antenatal and postnatal management. Pediatr Surg Int 2008; 24:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/5\">",
"      Abbey P, Das CJ, Pangtey GS, et al. Imaging in bronchopulmonary sequestration. J Med Imaging Radiat Oncol 2009; 53:22.",
"     </a>",
"    </li>",
"    <li>",
"     Epelman, M. Semin Ultrasound CT MRI 2010; 31:141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/7\">",
"      Nijagal A, Jelin E, Feldstein VA, et al. The diagnosis and management of intradiaphragmatic extralobar pulmonary sequestrations: a report of 4 cases. J Pediatr Surg 2012; 47:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/8\">",
"      Maas KL, Feldstein VA, Goldstein RB, Filly RA. Sonographic detection of bilateral fetal chest masses: report of three cases. J Ultrasound Med 1997; 16:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/9\">",
"      Hubbard AM, Adzick NS, Crombleholme TM, et al. Congenital chest lesions: diagnosis and characterization with prenatal MR imaging. Radiology 1999; 212:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/10\">",
"      Sepulveda W. Perinatal imaging in bronchopulmonary sequestration. J Ultrasound Med 2009; 28:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/11\">",
"      Daltro P, Werner H, Gasparetto TD, et al. Congenital chest malformations: a multimodality approach with emphasis on fetal MR imaging. Radiographics 2010; 30:385.",
"     </a>",
"    </li>",
"    <li>",
"     Pariente, G. J Ultrasound in Medicine 2009; 28:1081.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/13\">",
"      Zeidan S, Gorincour G, Potier A, et al. Congenital lung malformation: evaluation of prenatal and postnatal radiological findings. Respirology 2009; 14:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/14\">",
"      Bush A, Hogg J, Chitty LS. Cystic lung lesions - prenatal diagnosis and management. Prenat Diagn 2008; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/15\">",
"      Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998; 179:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/16\">",
"      Breysem L, Bosmans H, Dymarkowski S, et al. The value of fast MR imaging as an adjunct to ultrasound in prenatal diagnosis. Eur Radiol 2003; 13:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/17\">",
"      Lecomte B, Hadden H, Coste K, et al. Hyperechoic congenital lung lesions in a non-selected population: from prenatal detection till perinatal management. Prenat Diagn 2009; 29:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/18\">",
"      Grethel EJ, Wagner AJ, Clifton MS, et al. Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience. J Pediatr Surg 2007; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/19\">",
"      Gerle RD, Jaretzki A 3rd, Ashley CA, Berne AS. Congenital bronchopulmonary-foregut malformation. Pulmonary sequestration communicating with the gastrointestinal tract. N Engl J Med 1968; 278:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/20\">",
"      Knox EM, Kilby MD, Martin WL, Khan KS. In-utero pulmonary drainage in the management of primary hydrothorax and congenital cystic lung lesion: a systematic review. Ultrasound Obstet Gynecol 2006; 28:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/21\">",
"      Bruner JP, Jarnagin BK, Reinisch L. Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late? Fetal Diagn Ther 2000; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/22\">",
"      Mann S, Wilson RD, Bebbington MW, et al. Antenatal diagnosis and management of congenital cystic adenomatoid malformation. Semin Fetal Neonatal Med 2007; 12:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/23\">",
"      Wilson RD. In utero therapy for fetal thoracic abnormalities. Prenat Diagn 2008; 28:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/24\">",
"      Witlox RS, Lopriore E, Walther FJ, et al. Single-needle laser treatment with drainage of hydrothorax in fetal bronchopulmonary sequestration with hydrops. Ultrasound Obstet Gynecol 2009; 34:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/25\">",
"      Oepkes D, Devlieger R, Lopriore E, Klumper FJ. Successful ultrasound-guided laser treatment of fetal hydrops caused by pulmonary sequestration. Ultrasound Obstet Gynecol 2007; 29:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/26\">",
"      Ruano R, de A Pimenta EJ, Marques da Silva M, et al. Percutaneous intrauterine laser ablation of the abnormal vessel in pulmonary sequestration with hydrops at 29 weeks' gestation. J Ultrasound Med 2007; 26:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/27\">",
"      Ruano R, da Silva MM, Salustiano EM, et al. Percutaneous laser ablation under ultrasound guidance for fetal hyperechogenic microcystic lung lesions with hydrops: a single center cohort and a literature review. Prenat Diagn 2012; 32:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10919/abstract/28\">",
"      Mychaliska GB, Bryner BS, Nugent C, et al. Giant pulmonary sequestration: the rare case requiring the EXIT procedure with resection and ECMO. Fetal Diagn Ther 2009; 25:163.",
"     </a>",
"    </li>",
"    <li>",
"     Adzick, NS. Open fetal surgery for life-threatening fetal anomalies. Semin Fetal Neonatal Med 2009. [Epub ahead of print].",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13515 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10919=[""].join("\n");
var outline_f10_42_10919=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31928973\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31928889\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31929161\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928895\">",
"      Imaging the normal fetal lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928901\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928907\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928913\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31928919\">",
"      - Congenital pulmonary airway malformation (CPAM)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31928925\">",
"      - Congenital lobar emphysema (CLE)/ congenital lobar overinflation (CLO)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31928931\">",
"      - Congenital diaphragmatic hernia (CDH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31928937\">",
"      - Neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31928943\">",
"      - Adrenal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928949\">",
"      Prenatal course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928955\">",
"      Prenatal management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928961\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31928967\">",
"      Postnatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31928973\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/13515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/13515|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/14/44257\" title=\"diagnostic image 1\">",
"      Prenatal ultrasound image of a normal fetal chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/54/8035\" title=\"diagnostic image 2\">",
"      MR normal fetal chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/5/31829\" title=\"diagnostic image 3\">",
"      Fetal intralobar sequestration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/27/16822\" title=\"diagnostic image 4\">",
"      Extralobar sequestration at 32 weeks of gestation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42169?source=related_link\">",
"      Congenital diaphragmatic hernia: Prenatal diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=related_link\">",
"      Congenital lobar emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32456?source=related_link\">",
"      Overview of echogenic masses and calcification in the fetal abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=related_link\">",
"      Prenatal diagnosis and management of congenital pulmonary airway malformation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10920="Insulin aspart: Drug information";
var content_f10_42_10920=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin aspart: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/14/229?source=see_link\">",
"    see \"Insulin aspart: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/50/24358?source=see_link\">",
"    see \"Insulin aspart: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2104823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoLOG&reg;;",
"     </li>",
"     <li>",
"      NovoLOG&reg; FlexPen&reg;;",
"     </li>",
"     <li>",
"      NovoLOG&reg; Penfill&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2104824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NovoRapid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2104827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Rapid-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2104863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin aspart is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin aspart has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin aspart may also be administered I.V. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial total insulin dose:",
"     </b>",
"     0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (&ldquo;conventional therapy&rdquo;):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, insulin aspart) or short-acting form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin (insulin aspart) as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (&ldquo;intensive therapy&rdquo;):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin (eg, insulin aspart) formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2104862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/50/24358?source=see_link\">",
"      see \"Insulin aspart: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     Children &ge;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Diabetic ketoacidosis (DKA), mild-to-moderate (unlabeled use):",
"     </b>",
"     Children and Adolescents: Treatment should continue until reversal of acid-base derangement/ketonemia. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ (",
"     <b>",
"      Note:",
"     </b>",
"     Use of I.V. regular insulin is preferred; only use the SubQ route if I.V. infusion access is unavailable): 0.3 units/kg  followed in 1 hour by 0.1 units/kg given every hour or 0.15-0.2 units/kg every 2 hours; continue until acidosis clears, then decrease to 0.05 units/kg given every hour until maintenance SubQ replacement dosing can be initiated (Kitabchi, 2004; Wolfsdorf, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2307924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2104864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5994930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg;: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg; FlexPen&reg;: 100 units/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg; Penfill&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2142861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2104866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Insulin aspart should be administered immediately (within 5-10 minutes) before a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites. When mixing insulin aspart with other preparations of insulin (eg, insulin NPH), insulin aspart should be drawn into syringe first. Do not dilute or mix other insulin formulations with insulin aspart contained in a cartridge or prefilled pen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CSII administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets and infusion set insertion sites should be changed at least every 3 days; rotate infusion sites. Do not dilute or mix other insulin formulations with insulin aspart that is to be used in an external insulin pump.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered I.V. with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required.",
"     <b>",
"      Do not administer insulin mixtures intravenously.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusions: To minimize adsorption to I.V. solution bag:",
"     <b>",
"      Note:",
"     </b>",
"     Refer to institution-specific protocols where appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      If new tubing is",
"     </i>",
"     <b>",
"      <i>",
"       not",
"      </i>",
"     </b>",
"     <i>",
"      needed:",
"     </i>",
"     Wait a minimum of 30 minutes between the preparation of the solution and the initiation of the infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If new tubing is needed: After receiving the insulin drip solution, the administration set should be attached to the I.V. container and the entire line should be flushed with a priming infusion of 20-50 mL of the insulin solution (Goldberg, 2006; Hirsch, 2006). Wait 30 minutes, and then flush the line again with the insulin solution prior to initiating the infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Because of adsorption, the actual amount of insulin being administered via I.V. infusion could be substantially less than the apparent amount. Therefore, adjustment of the I.V. infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi, 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1-4 hours prior to the discontinuation of I.V. insulin to prevent hyperglycemia (Moghissi, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2104852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, and NS.",
"     <b>",
"      Note:",
"     </b>",
"     Insulin Diluting Medium for NovoLog&reg; is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine, insulin glulisine, insulin lispro, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2104830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8092856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gestational diabetes mellitus (GDM); mild-to-moderate diabetic ketoacidosis (DKA); mild-to-moderate hyperosmolar hyperglycemic state (HHS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2105009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NovoLOG&reg; may be confused with HumaLOG&reg;, HumuLIN&reg; R, Nimbex&reg;, NovoLIN&reg; N, NovoLIN&reg; R, NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2104841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2104835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin aspart or any component of the formulation; during episodes of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2104836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with I.V. use and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of sliding scale insulin in this population due to increased risk of hypoglycemia without benefits in management of hyperglycemia regardless of care setting (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin or via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin [eg, insulin aspart]) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Due to the short duration of action of insulin aspart, a longer acting insulin or CSII via an external insulin pump is needed to maintain adequate glucose control in patients with type 1 diabetes mellitus (insulin dependent, IDDM). In both type 1 and type 2 diabetes, preprandial administration of insulin aspart should be immediately followed by a meal within 5-10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CSII administration: May be administered via CSII; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SubQ insulin administration may be required until the problem is identified and corrected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Insulin aspart may be administered I.V. in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8101785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2104847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2104849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2104831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2104832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. Insulin aspart has been demonstrated to be as safe and effective as regular human insulin when used during pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2104833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2104834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if insulin aspart distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2104865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NovoLOG FlexPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $65.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NovoLOG PenFill Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $63.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NovoLOG Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $170.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2104868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. administration: Close monitoring of blood glucose and serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2104855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Insulina Novorapid (AR, UY);",
"     </li>",
"     <li>",
"      NovoMix 30 (AT, BE, BG, CH, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Novomix 30 (MX);",
"     </li>",
"     <li>",
"      Novomix 50 (FR);",
"     </li>",
"     <li>",
"      Novomix 70 (FR);",
"     </li>",
"     <li>",
"      Novorapid (AT, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, ID, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Novorapid Flexpen (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2104853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; it also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae.",
"     </i>",
"     Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin aspart is a rapid-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2104856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: 0.2-0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Peak effect: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: SubQ: 81 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 40-50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins, &ldquo;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 30, September 2001 (Replaces Technical Bulletin Number 200, December 1994). Gestational Diabetes,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2001, 98(3):525-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/11547793/pubmed\" id=\"11547793\" target=\"_blank\">",
"        11547793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Gestational Diabetes Mellitus,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1):88-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/14693936/pubmed\" id=\"14693936\" target=\"_blank\">",
"        14693936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 2008, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo;",
"      <i>",
"       Diabet Med",
"      </i>",
"      , 2006, 23(7):736-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/16842477/pubmed\" id=\"16842477\" target=\"_blank\">",
"        16842477",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg PA, Kedves A, Walter K, et al, &ldquo;'Waste Not, Want Not': Determining Optimal Priming Volume for Intravenous Insulin Infusions,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):598-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/17037974/pubmed\" id=\"17037974\" target=\"_blank\">",
"        17037974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heller S, McCance DR, Moghissi E, et al, \"Diversity in Diabetes: The Role of Insulin Aspart,\"",
"      <i>",
"       Diabetes Metab Res Rev",
"      </i>",
"      , 2012, 28(1):50-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/21695769/pubmed\" id=\"21695769\" target=\"_blank\">",
"        21695769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch IB, &ldquo;Evidence-Based Priming,&rdquo;",
"      <i>",
"       Diabetes Technol Ther",
"      </i>",
"      , 2006, 8(5):521-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/17037966/pubmed\" id=\"17037966\" target=\"_blank\">",
"        17037966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Miles JM, et al, &ldquo;Hyperglycemic Crises in Adult Patients With Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(7):1335-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/19564476/pubmed\" id=\"19564476\" target=\"_blank\">",
"        19564476",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kitabchi AE, Umpierrez GE, Murphy MB, et al, \"Hyperglycemic Crises in Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(Suppl 1): 94-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/14693938/pubmed\" id=\"14693938\" target=\"_blank\">",
"        14693938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(4):353-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/19454396/pubmed\" id=\"19454396\" target=\"_blank\">",
"        19454396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nathan DM, Buse, JB, Davidson MB, et al, &ldquo;Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):193-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/18945920/pubmed\" id=\"18945920\" target=\"_blank\">",
"        18945920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riddle MC, Rosenstock J, Gerich J, et al, &ldquo;The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3080-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/14578243/pubmed\" id=\"14578243\" target=\"_blank\">",
"        14578243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Umpierrez GE, Cuervo R, Karabell A, et al, \"Treatment of Diabetic Ketoacidosis With Subcutaneous Insulin Aspart,\"",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(8):1873-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/15277410/pubmed\" id=\"15277410\" target=\"_blank\">",
"        15277410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Umpierrez GE, Jones S, Smiley D, et al, \"Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis: A Randomized Controlled Trial,\"",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2009, 32(7):1164-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/19366972/pubmed\" id=\"19366972\" target=\"_blank\">",
"        19366972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo;",
"      <i>",
"       Pediatr Diabetes",
"      </i>",
"      , 2007, 8(1):28-43. Available at file://www.ispad.org/FileCenter/10-Wolfsdorf_Ped_Diab_2007,8.28-43.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10920/abstract-text/17341289/pubmed\" id=\"17341289\" target=\"_blank\">",
"        17341289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9020 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10920=[""].join("\n");
var outline_f10_42_10920=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104823\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104824\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104827\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104863\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104862\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307924\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104864\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994930\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104880\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2142861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104866\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104852\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104830\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8092856\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104841\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104835\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104836\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101785\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104849\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104832\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104833\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104834\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104865\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422170\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104868\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104855\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869465\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104856\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9020\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9020|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/14/229?source=related_link\">",
"      Insulin aspart: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/50/24358?source=related_link\">",
"      Insulin aspart: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10921="Fluorouracil (systemic): Drug information";
var content_f10_42_10921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=see_link\">",
"    see \"Fluorouracil (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=see_link\">",
"    see \"Fluorouracil (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8100784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8100806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8100811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8100893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should be consulted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CEF regimen:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 every 28 days (in combination with cyclophosphamide and epirubicin) for 6 cycles (Levine, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CMF regimen:",
"     </i>",
"     600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 every 28 days (in combination with cyclophosphamide and methotrexate) for 6 cycles (Goldhirsch, 1998; Levine, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      FAC regimen:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 every 21-28 days (in combination with cyclophosphamide and doxorubicin) for 6 cycles (Assikis, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      FLOX regimen:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus on days 1, 8, 15, 22, 29, and 36 (1 hour after leucovorin) every 8 weeks (in combination with leucovorin and oxaliplatin) for 3 cycles (Kuebler, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      FOLFOX6 and mFOLFOX6 regimen:",
"     </i>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus on day 1, followed by 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 2 days (over 46 hours) every 2 weeks (in combination with leucovorin and oxaliplatin) until disease progression or unacceptable toxicity (Cheeseman, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      FOLFIRI regimen:",
"     </i>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus on day 1, followed by 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 2 days (over 46 hours) every 2 weeks (in combination with leucovorin and irinotecan) until disease progression or unacceptable toxicity; after 2 cycles, may increase continuous infusion fluorouracil dose to 1500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (over 46 hours) (Andre, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Roswell Park regimen:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (bolus) on days 1, 8, 15, 22, 29, and 36 (1 hour after leucovorin) every 8 weeks (in combination with leucovorin) for 4 cycles (Haller, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gastric cancer (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CF regimen:",
"     </i>",
"     750-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 and 29-32 of a 35-day treatment cycle (preoperative chemoradiation; in combination with cisplatin) (Tepper, 2008; NCCN Gastric Cancer Guidelines v2.2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ECF regimen (resectable disease):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-21 every 3 weeks (in combination with epirubicin and cisplatin) for 6 cycles (3 cycles preoperatively and 3 cycles postoperatively) (Cunningham, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ECF or EOF regimen (advanced disease):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-21 every 3 weeks (in combination with epirubicin and either cisplatin or oxaliplatin) for a planned duration of 24 weeks (Sumpter, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      TCF or DCF regimen:",
"     </i>",
"     750  mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 3 weeks or 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 4 weeks (in combination with docetaxel and cisplatin) until disease progression or unacceptable toxicity (Ajani, 2007; Van Cutsem, 2006; NCCN Gastric Cancer Guidelines v2.2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ToGA regimen (HER2-positive):",
"     </i>",
"     800 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 3 weeks (in combination with cisplatin and trastuzumab) until disease progression or unacceptable toxicity (Bang, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatic cancer (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chemoradiation therapy:",
"     </i>",
"     250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 3 weeks prior to and then throughout radiation therapy (Regine, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Fluorouracil-Leucovorin:",
"     </i>",
"     425 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (bolus) days 1-5 every 28 days (in combination with leucovorin) for 6 cycles (Neoptolemos, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      FOLFIRINOX regimen:",
"     </i>",
"     400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus on day 1, followed by 1200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 2 days (over 46 hours) every 14 days (in combination with leucovorin, irinotecan, and oxaliplatin) until disease progression or unacceptable toxicity for a recommended 12 cycles (Conroy, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anal carcinoma (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 and days 29-32 (in combination with mitomycin and radiation therapy) (Ajani, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bladder cancer (unlabeled use):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 and days 16-20 (in combination with mitomycin and radiation therapy) (James, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cervical cancer (unlabeled use):",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 (in combination with cisplatin and radiation therapy) every 3 weeks for 3 cycles (Eifel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Esophageal cancer (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CF regimen:",
"     </i>",
"     750-1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 and 29-32 of a 35-day treatment cycle (preoperative chemoradiation; in combination with cisplatin) (Tepper, 2008; NCCN Esophageal and Esophagogastric Junction Cancers Guidelines v2.2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ECF regimen (resectable disease):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-21 every 3 weeks (in combination with epirubicin and cisplatin) for 6 cycles (3 cycles preoperatively and 3 cycles postoperatively) (Cunningham, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ECF or EOF regimen (advanced disease):",
"     </i>",
"     200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-21 every 3 weeks (in combination with epirubicin and either cisplatin or oxaliplatin) for a planned duration of 24 weeks  (Sumpter, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      TCF or DCF regimen:",
"     </i>",
"     750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 3 weeks or 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 4 weeks (in combination with docetaxel and cisplatin) until disease progression or unacceptable toxicity (Ajani, 2007; Van Cutsem, 2006; NCCN Esophageal and Esophagogastric Junction Cancers Guidelines v2.2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Head and neck cancer, squamous cell (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Platinum-Fluorouracil regimen:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 every 3 weeks (in combination with cisplatin) for at least 6 cycles (Gibson, 2005)",
"     <b>",
"      or",
"     </b>",
"     600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4, 22-25, and 43-46 (in combination with carboplatin and radiation) (Denis, 2004; Bourhis, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      TPF regimen:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 every 3 weeks (in combination with docetaxel and cisplatin) for 3 cycles, and followed by chemoradiotherapy (Posner, 2007)",
"     <b>",
"      or",
"     </b>",
"     750 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-5 every 3 weeks (in combination with docetaxel and cisplatin) for up to 4 cycles (Vermorken, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Platinum, 5-FU, and cetuximab regimen:",
"     </i>",
"     1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion days 1-4 every 3 weeks (in combination with either cisplatin or carboplatin and cetuximab) for a total of up to 6 cycles (Vermorken, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hepatobiliary cancer (unlabeled use):",
"     </b>",
"     I.V.: 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (bolus) on days 1, 8, and 15 every 4 weeks (in combination with gemcitabine and leucovorin) (Alberts, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8100894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8100895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, extreme caution should be used in patients with renal impairment. The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute and continuous renal replacement therapy (CRRT): No dosage adjustment necessary (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administer standard dose following hemodialysis on dialysis days (Janus, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Administer 50% of standard dose following hemodialysis (Aronoff, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8100896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, extreme caution should be used in patients with hepatic impairment. The following adjustments have been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Floyd, 2006: Bilirubin &gt;5 mg/dL: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Koren, 1992: Hepatic impairment (degree not specified): Administer &lt;50% of dose, then increase if toxicity does not occur.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15832178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      According to the manufacturer, treatment should be discontinued for the following:",
"     </i>",
"     Stomatitis or esophagopharyngitis, leukopenia (WBC &lt;3500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), rapidly falling white blood cell count, intractable vomiting, diarrhea, frequent bowel movements, watery stools, gastrointestinal ulcer or bleeding, thrombocytopenia (platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 50 mg/mL (10 mL, 20 mL, 50 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrucil&reg;: 50 mg/mL (10 mL, 50 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8100809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8100907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.: Administration rate varies by protocol; refer to specific reference for protocol. May be administered by I.V. push, I.V. bolus, or as a continuous infusion. Avoid extravasation (may be an irritant).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8100860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, anidulafungin, aztreonam, bleomycin, cefepime, cisplatin, cyclophosphamide, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, fludarabine, furosemide, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, leucovorin calcium, linezolid, mannitol, melphalan, methotrexate, metoclopramide, mitomycin, paclitaxel, palonosetron, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aldesleukin, amphotericin B cholesteryl sulfate complex, droperidol, filgrastim, topotecan, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Gallium nitrate, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8100826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast cancer, colon cancer, rectal cancer, pancreatic cancer, and stomach (gastric) cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F9295500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anal cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck cancer, hepatobiliary cancers, neuroendocrine tumors, penile cancer (metastatic), thymic cancers, and unknown primary cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8100786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluorouracil may be confused with flucytosine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8100835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Toxicity depends on duration of treatment and/or rate of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, heart failure, MI, myocardial ischemia, vasospasm, ventricular ectopy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Acute cerebellar syndrome, confusion, disorientation, euphoria, headache, nystagmus, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, dry skin, fissuring, nail changes (nail loss), palmar-plantar erythrodysesthesia syndrome, pruritic maculopapular rash, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, vein pigmentation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, bleeding, diarrhea, esophagopharyngitis, mesenteric ischemia (acute), nausea, sloughing, stomatitis, ulceration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, leukopenia (nadir: days 9-14; recovery by day 30), pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, lacrimal duct stenosis, photophobia, visual changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, generalized allergic reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8100831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorouracil or any component of the formulation; poor nutritional states; depressed bone marrow function; potentially serious infections",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8100832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hand-foot syndrome: Palmar-plantar erythrodysesthesia (hand-foot) syndrome has been associated with use. Symptoms include a tingling sensation, which may progress to pain, and then to symmetrical swelling and erythema with tenderness; desquamation may occur. With treatment interruption, generally resolves over 5-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Toxicity: Discontinue if intractable vomiting, diarrhea, precipitous fall in leukocyte or platelet counts, myocardial ischemia, hemorrhage, gastrointestinal ulcer or bleeding, stomatitis, or esophagopharyngitis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dihydropyrimidine dehydrogenase deficiency (DPD): Administration to patients with genetic DPD has been associated with prolonged clearance and increased toxicity (diarrhea, neutropenia, and neurotoxicity) following administration; rechallenge has resulted in recurrent toxicity (despite dose reduction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metastatic disease: Use with caution in patients with widespread metastatic marrow involvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alkylating agents: Use with caution in poor-risk patients who have had previous use of alkylating agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pelvic radiation recipients: Use with caution in poor-risk patients who have had high-dose pelvic radiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. The manufacturer&rsquo;s labeling recommends hospitalizing patients during the first treatment course due to the potential for severe toxicity.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9844112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8100851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fluorouracil (Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fluorouracil (Systemic) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Fluorouracil (Systemic). SORAfenib may increase the serum concentration of Fluorouracil (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fluorouracil (Systemic) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8100855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid black cohosh, dong quai in estrogen-dependent tumors.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8100827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8100828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects (increased resorptions, embryolethality, and teratogenicity) have been observed in animal reproduction studies. Based on the mechanism of action, fluorouracil may cause fetal harm if administered during pregnancy (according to the manufacturer&rsquo;s labeling). The National Comprehensive Cancer Network (NCCN) breast cancer guidelines (v.3.2012) state that chemotherapy, if indicated, may be administered to pregnant women with breast cancer as part of a combination chemotherapy regimen (common regimens administered during pregnancy include  doxorubicin, cyclophosphamide, and fluorouracil); chemotherapy should not be administered during the first trimester, after 35 weeks gestation, or within 3 weeks of planned delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8100830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15830778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on the mechanism of action, the manufacturer&rsquo;s labeling recommends against breastfeeding if receiving fluorouracil.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8100906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of thiamine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8100925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adrucil Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $23.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $39.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/10 mL (10 mL): $6.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorouracil Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/20 mL (20 mL): $6.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 gm/50 mL (50 mL): $15.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 g/100 mL (100 mL): $27.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/10 mL (10 mL): $3.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8100911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, renal function tests, liver function tests, signs of palmar-plantar erythrodysesthesia syndrome, stomatitis, diarrhea, hemorrhage, or gastrointestinal ulcers or bleeding",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      5-FU (DE);",
"     </li>",
"     <li>",
"      Curacil (ID);",
"     </li>",
"     <li>",
"      Fivoflu (IN, PH, VE);",
"     </li>",
"     <li>",
"      Flonida (IN);",
"     </li>",
"     <li>",
"      Fluonco (PH);",
"     </li>",
"     <li>",
"      Flurablastin (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Fluracedyl (BE, MY, NL, PH);",
"     </li>",
"     <li>",
"      Fluroblastin (VE);",
"     </li>",
"     <li>",
"      Fluroblastine (BE);",
"     </li>",
"     <li>",
"      Fu Ke (CL);",
"     </li>",
"     <li>",
"      La-Fu (CZ);",
"     </li>",
"     <li>",
"      Pharmauracil (PK);",
"     </li>",
"     <li>",
"      Ribofluor (DE);",
"     </li>",
"     <li>",
"      Sinofuan Implant (CL);",
"     </li>",
"     <li>",
"      Triosules (AR);",
"     </li>",
"     <li>",
"      Utoral (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8100861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pyrimidine analog antimetabolite that interferes with DNA and RNA synthesis; after activation, F-UMP (an active metabolite) is incorporated into RNA to replace uracil and inhibit cell growth; the active metabolite F-dUMP, inhibits thymidylate synthetase, depleting thymidine triphosphate (a necessary component of DNA synthesis).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8100876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates extracellular fluid, CSF, and third space fluids (eg, pleural effusions and ascitic fluid), marrow, intestinal mucosa, liver and other tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (90%); via a dehydrogenase enzyme; FU must be metabolized to be active metabolites, 5-fluoroxyuridine monophosphate (F-UMP) and 5-5-fluoro-2&rsquo;-deoxyuridine-5&rsquo;-O-monophosphate (F-dUMP)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 16 minutes (range: 8-20 minutes); two metabolites, F-dUMP and F-UMP, have prolonged half-lives depending on the type of tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily metabolized in the liver; excreted in lung (as expired CO",
"     <sub>",
"      2",
"     </sub>",
"     ) and urine (7% to 20% as unchanged drug within 6 hours; also as metabolites within 9-10 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Moiseyenko VM, Tjulandin S, et al, \"Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(22):3210-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17664468/pubmed\" id=\"17664468\" target=\"_blank\">",
"        17664468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Winter KA, Gunderson LL, et al, &ldquo;Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(16):1914-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/18430910/pubmed\" id=\"18430910\" target=\"_blank\">",
"        18430910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alberts SR, Al-Khatib H, Mahoney MR, et al, &ldquo;Gemcitabine, 5-Fluorouracil, and Leucovorin in Advanced Biliary Tract and Gallbladder Carcinoma: A North Central Cancer Treatment Group Phase II Trial,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2005, 103(1):111-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/15558814/pubmed\" id=\"15558814\" target=\"_blank\">",
"        15558814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andr&eacute; T, Louvet C, Maindrault-Goebel F, et al, \"CPT-11 (Irinotecan) Addition to Bimonthly, High-Dose Leucovorin and Bolus and Continuous-Infusion 5-Fluorouracil (FOLFIRI) for Pretreated Metastatic Colorectal Cancer. GERCOR,\"",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1999, 35(9):1343-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/10658525/pubmed\" id=\"10658525\" target=\"_blank\">",
"        10658525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assikis V, Buzdar A, Yang Y, et al, &ldquo;A Phase III Trial of Sequential Adjuvant Chemotherapy for Operable Breast Carcinoma: Final Analysis With 10-Year Follow-Up,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 97(11):2716-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/12767083/pubmed\" id=\"12767083\" target=\"_blank\">",
"        12767083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bamat MK, Tremmel R, O&rsquo;Neil JD, et al, &ldquo;Uridine Triacetate: An Orally Administered Life-Saving Antidote for 5-FU Overdose,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 28(15s):9084 [abstract 9084 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bang YJ, Van Cutsem E, Feyereislova A, et al, \"Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9742):687-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/20728210/pubmed\" id=\"20728210\" target=\"_blank\">",
"        20728210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benaji B, Faouzi MA, Dine T, et al, &ldquo;Compatibility Study of 5-Fluorouracil With PVC Bags After Repackaging Into Two Types of Infusion Admixtures,&rdquo;",
"      <i>",
"       Therapie",
"      </i>",
"      , 1999, 54(5):659-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/10667105/pubmed\" id=\"10667105\" target=\"_blank\">",
"        10667105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berry DL, Theriault RL, Holmes FA, et al, \"Management of Breast Cancer During Pregnancy Using a Standardized Protocol,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(3):855-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/10071276/pubmed\" id=\"10071276\" target=\"_blank\">",
"        10071276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bourhis J, Sire C, Graff P, et al, &ldquo;Concomitant Chemoradiotherapy versus Acceleration of Radiotherapy With or Without Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): An Open-Label Phase 3 Randomised Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(2):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/22261362/pubmed\" id=\"22261362\" target=\"_blank\">",
"        22261362",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buzdar AU, Kau SW, Smith TL, et al, &ldquo;Ten-Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 1989, 12(2):123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/2705401/pubmed\" id=\"2705401\" target=\"_blank\">",
"        2705401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheeseman SL, Joel SP, Chester JD, et al, &ldquo;A &lsquo;Modified de Gramont&rsquo; Regimen of Fluorouracil, Alone and With Oxaliplatin, for Advanced Colorectal Cancer,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2002, 87(4):393-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/12177775/pubmed\" id=\"12177775\" target=\"_blank\">",
"        12177775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy T, Desseigne F, Ychou M, et al, &ldquo;FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(19):1817-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/21561347/pubmed\" id=\"21561347\" target=\"_blank\">",
"        21561347",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Allum WH, Stenning SP, et al, \"Perioperative Chemotherapy Versus Surgery Alone for Resectable Gastroesophageal Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(1):11-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/16822992/pubmed\" id=\"16822992\" target=\"_blank\">",
"        16822992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Denis F, Garaud P, Bardet E, et al, &ldquo;Final Results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(1):69-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/14657228 /pubmed\" id=\"14657228 \" target=\"_blank\">",
"        14657228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diasio RB and Johnson MR, &ldquo;The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy With 5-Fluorouracil,&rdquo;",
"      <i>",
"       Pharmacology",
"      </i>",
"      , 2000, 61(3):199-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/10971206/pubmed\" id=\"10971206\" target=\"_blank\">",
"        10971206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JE, Garrett AM, Shyr Y, et al, &ldquo;A Randomized Phase II Trial in Patients With Carcinoma of an Unknown Primary Site,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 91(3):592-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/11169943/pubmed\" id=\"11169943\" target=\"_blank\">",
"        11169943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eifel PJ, Winter K, Morris M, et al, &ldquo;Pelvic Irradiation With Concurrent Chemotherapy versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(5):872-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/14990643/pubmed\" id=\"14990643\" target=\"_blank\">",
"        14990643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forastiere AA, Metch B, Schuller DE, et al, \"Randomized Comparison of Cisplatin Plus Fluorouracil and Carboplatin Plus Fluorouracil Versus Methotrexate in Advanced Squamous-Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1992, 10(8):1245-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/1634913/pubmed\" id=\"1634913\" target=\"_blank\">",
"        1634913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fournet A, Gilard V, Malet-Martino M, et al, &ldquo;Stability of Commercial Solutions of 5-Fluorouracil for Continuous Infusion in an Ambulatory Pump,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2000, 46(6):501-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/11138464/pubmed\" id=\"11138464\" target=\"_blank\">",
"        11138464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibson MK, Li Y, Murphy B, et al, \"Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(15):3562-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/15908667/pubmed\" id=\"15908667\" target=\"_blank\">",
"        15908667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldhirsch A, Colleoni M, Coates AS, et al, &ldquo;Adding Adjuvant CMF Chemotherapy to Either Radiotherapy or Tamoxifen: Are All CMFs Alike? The International Breast Cancer Study Group (IBCSG),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 1998, 9(5):489-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/9653488/pubmed\" id=\"9653488\" target=\"_blank\">",
"        9653488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunderson LL, Winter KA, Ajani JA, et al, &ldquo;Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin versus Fluorouracil/Cisplatin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(35):4344-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/23150707/pubmed\" id=\"23150707\" target=\"_blank\">",
"        23150707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hahn KM, Johnson PH, Gordon N, et al, \"Treatment of Pregnant Breast Cancer Patients and Outcomes of Children Exposed to Chemotherapy",
"      <i>",
"       In utero",
"      </i>",
"      ,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 107(6):1219-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/16894524/pubmed\" id=\"16894524\" target=\"_blank\">",
"        16894524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haller DG, Catalano PJ, Macdonald JS, et al, &ldquo;Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(34):8671-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/16314627/pubmed\" id=\"16314627\" target=\"_blank\">",
"        16314627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hezel AF and Zhu AX, &ldquo;Systemic Therapy for Biliary Tract Cancers,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2008, 13(4):415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/18448556/pubmed\" id=\"18448556\" target=\"_blank\">",
"        18448556",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James ND, Hussain SA, Hall E, et al, &ldquo;Radiotherapy With or Without Chemotherapy in Muscle-Invasive Bladder Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(16):1477-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/22512481/pubmed\" id=\"22512481\" target=\"_blank\">",
"        22512481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, \"Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G, Beatty K, Seto A, et al, &ldquo;The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992,  26(3):363-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/1554959/pubmed\" id=\"1554959\" target=\"_blank\">",
"        1554959",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kouvaraki MA, Ajani JA, Hoff P, et al, &ldquo;Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(23):4762-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/15570077/pubmed\" id=\"15570077\" target=\"_blank\">",
"        15570077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      KueblerJP, Wieand HS, O'Connell MJ, et al, &ldquo;Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(16):2198-204.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17470851/pubmed\" id=\"17470851\" target=\"_blank\">",
"        17470851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kusaba H, Shibata Y, Arita S, et al, &ldquo;Infusional 5-Fluorouracil and Cisplatin as First-Line Chemotherapy in Patients With Carcinoma of Unknown Primary Site,&rdquo;",
"      <i>",
"       Med Oncol",
"      </i>",
"      , 2007, 24(2):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17848753/pubmed\" id=\"17848753\" target=\"_blank\">",
"        17848753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine MN, Bramwell VH, Pritchard KI, et al, &ldquo;Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer, National Cancer Institute of Canada Clinical Trials Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(8):2651-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/9704715 /pubmed\" id=\"9704715 \" target=\"_blank\">",
"        9704715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martel P, Petit I, Pinguet F, et al, &ldquo;Long-Term Stability of 5-Fluorouracil Stored in PVC Bags and in Ambulatory Pump Reservoirs,&rdquo;",
"      <i>",
"       J Pharm Biomed Anal",
"      </i>",
"      , 1996, 14(4):395-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/8729637/pubmed\" id=\"8729637\" target=\"_blank\">",
"        8729637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milano G and Chamorey AL, &ldquo;Clinical Pharmacokinetics of 5-Fluorouracil With Consideration of Chronopharmacokinetics,&rdquo;",
"      <i>",
"       Chronobiol Int",
"      </i>",
"      , 2002, 19(1):177-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/11962674/pubmed\" id=\"11962674\" target=\"_blank\">",
"        11962674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 3.2012. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Esophageal and Esophagogastric Junction Cancers,&rdquo; Version 2.2012. Available at  file://www.nccn.org/professionals/physician_gls/PDF/esophageal.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Gastric Cancer,&rdquo; Version 2.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/gastric.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neoptolemos JP, Stocken DD, Bassi C, et al, &ldquo;Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid Vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(10):1073-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/20823433/pubmed\" id=\"20823433\" target=\"_blank\">",
"        20823433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelzer U, Schwaner I, Stieler J, et al, &ldquo;Best Supportive Care (BSC) versus Oxaliplatin, Folinic Acid and 5-Fluorouracil (OFF) Plus BSC in Patients for Second-Line Advanced Pancreatic Cancer: A Phase III-Study From the German CONKO-Study Group,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(11):1676-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/21565490/pubmed\" id=\"21565490\" target=\"_blank\">",
"        21565490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Posner MR, Hershock DM, Blajman CR, et al, \"Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1705-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17960013/pubmed\" id=\"17960013\" target=\"_blank\">",
"        17960013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regine WF, Winter KA, Abrams RA, et al, &ldquo;Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA,",
"      </i>",
"      2008, 299(9):1019-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/18319412/pubmed\" id=\"18319412\" target=\"_blank\">",
"        18319412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmitt J and Loehrer PJ Sr, &ldquo;The Role of Chemotherapy in Advanced Thymoma,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2010, 5(10 Suppl 4):357-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/20859133/pubmed\" id=\"20859133\" target=\"_blank\">",
"        20859133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shammas FV, Ous S, and Fossa SD, &ldquo;Cisplatin and 5-Fluorouracil in Advanced Cancer of the Penis,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 1992, 147(3):630-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/1538445/pubmed\" id=\"1538445\" target=\"_blank\">",
"        1538445",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiles ML, Allen LV, and Prince SJ, &ldquo;Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphone Hydrochloride, Lorazepam, and Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1996, 53(13):1583-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/8809281/pubmed\" id=\"8809281\" target=\"_blank\">",
"        8809281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sumpter K, Harper-Wynne C, Cunningham D, et al, &ldquo;Report of Two Protocol Planned Interim Analyses in a Randomized Multicenter Phase III Study Comparing Capecitabine With Fluorouracil and Oxaliplatin With Cisplatin in Patients With Advanced Oesophagogastric Cancer Receiving ECF,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2005, 92(11):1976-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/15928658/pubmed\" id=\"15928658\" target=\"_blank\">",
"        15928658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tepper J, Krasna MJ, Niedzwiecki D, et al, \"Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(7):1086-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/18309943/pubmed\" id=\"18309943\" target=\"_blank\">",
"        18309943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Martinez JF, and Xu QA, &ldquo;Incompatibility of Fluorouracil With Leucovorin Calcium or Levoleucovorin Calcium,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(7):710-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/7627739/pubmed\" id=\"7627739\" target=\"_blank\">",
"        7627739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Moiseyenko VM, Tjulandin S, et al, \"Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(31):4991-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17075117/pubmed\" id=\"17075117\" target=\"_blank\">",
"        17075117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Mesia R, Rivera F, et al, \"Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(11):1116-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/18784101/pubmed\" id=\"18784101\" target=\"_blank\">",
"        18784101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Remenar E, van Herpen C, et al, \"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1695-1704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/42/10921/abstract-text/17960012/pubmed\" id=\"17960012\" target=\"_blank\">",
"        17960012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Borstel R, O&rsquo;Neil J, and Bamat M, &ldquo;Vistonuridine: An Orally Administered, Life-Saving Antidote for 5-Fluorouracil (5FU) Overdose,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15S):9616 [abstract 9616 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9131 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10921=[""].join("\n");
var outline_f10_42_10921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100784\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100806\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100811\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100893\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100894\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100895\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100896\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15832178\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100923\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100809\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100907\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100860\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100826\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9295500\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100786\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100835\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100831\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100832\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844112\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100851\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100855\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100827\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100828\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100830\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15830778\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100906\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100925\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100911\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961974\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100861\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100876\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9131\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9131|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=related_link\">",
"      Fluorouracil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=related_link\">",
"      Fluorouracil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/58/13221?source=related_link\">",
"      Fluorouracil (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=related_link\">",
"      Fluorouracil (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/52/29508?source=related_link\">",
"      Fluorouracil (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10922="Systemic chemotherapy for cancer in elderly persons";
var content_f10_42_10922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic chemotherapy for cancer in elderly persons",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Stuart M Lichtman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/42/10922/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/42/10922/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;People 65 years old or more are the fastest growing segment of the population in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/1\">",
"     1",
"    </a>",
"    ]. By 2030, this group will comprise about 20 percent of the total population, and among elderly persons, the percentage of patients &gt;75 and &gt;85 years old will increase disproportionately. A similar aging of the population is present in Western Europe and Japan.",
"   </p>",
"   <p>",
"    The importance of this demographic increase in the number of elderly persons is magnified by the sharp rise in the incidence of most types of cancer after age 60 years. Currently approximately 50 percent of all cancers and 70 percent of cancer deaths occur in those &ge;65 years old, and this fraction is expected to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the frequency with which cancer occurs in the elderly population, this group is significantly underrepresented in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Elderly patients who are enrolled in clinical trials represent a carefully selected subset. A systematic review of 345 cooperative group trials found no evidence of poorer survival or increased treatment-related mortality with experimental treatments compared to younger patients, despite concerns about an increased risk of toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even when substantial numbers of older patients are included, the results cannot be extrapolated to the entire elderly population. Patients with a poor performance status or renal, hepatic, or bone marrow dysfunction generally have been excluded, thus raising questions about the general applicability of data derived from such trials. This is particularly true for patients over 80 years.",
"   </p>",
"   <p>",
"    Challenges specific to older patients with advanced cancer and the treatment of common malignancies in the elderly population will be reviewed here. Detailed discussions of the therapy of specific malignancies are presented separately, and additional information on specific chemotherapy drugs can be found in the UpToDate drug database.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHALLENGES SPECIFIC TO ELDERLY PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential principles of treating advanced cancer in the elderly are the same as in younger patients. However, older patients, who may have age-related organ function decline and medical comorbidity, require special attention to the risks of chemotherapy (both treatment-related toxicity and quality of life [QOL] issues), particularly in the context of estimated life expectancy.",
"   </p>",
"   <p>",
"    The following age-related changes should be considered when assessing the risk of systemic chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age-related organ function decline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is commonly accompanied by a decline in the function of critical organ systems, and this declining organ function probably underlies age-related loss of physiologic reserve. Older patients with little reserve are at risk for decompensation upon exposure to severe stresses such as chemotherapy. This has several implications for elderly patients undergoing chemotherapy.",
"   </p>",
"   <p>",
"    Chronologic age may not correlate with physiologic impairment and decline in functional reserve, both of which vary substantially between individuals. Thus, treatment of cancer in elderly persons should focus on the extent of comorbidity and functional status rather than chronologic age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is associated with a decline in hepatic volume and hepatic blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As a result, drug metabolism and elimination may be slowed, potentially exposing patients to higher drug concentrations for longer periods of time. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Liver function and metabolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with a large burden of liver metastases may have a greater than expected degree of hepatic decompensation. In the setting of decreased volume of normal hepatic parenchyma, careful monitoring of liver function is recommended in older patients, particularly when drugs metabolized by the liver are being used. In addition, comorbidities such as alcohol abuse or a history of viral hepatitis may be relevant considerations in treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H8#H8\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Impact of preexisting liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function, as measured by the glomerular filtration rate (GFR) falls with age. However, age-related loss of muscle mass makes the serum creatinine concentration alone a less reliable as a marker of GFR in older patients. Estimation equations have been derived to estimate GFR. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Kidney function and drug excretion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the diminished renal reserve in elderly patients, volume depletion can lead to exaggerated reductions in renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, careful attention should be paid to fluid management in patients who develop chemotherapy-associated vomiting or diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bone marrow function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow reserve diminishes as a part of normal aging, placing older patients at greater risk for severe and prolonged chemotherapy-related cytopenias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/9\">",
"     9",
"    </a>",
"    ]. Dose reduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delay may be necessary; another alternative is the use of hematopoietic growth factor support during treatment. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Bone marrow'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal aging is associated with an increasing risk of coronary artery disease, an increased frequency and severity of valvular heart disease, and a decrease in ventricular compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/8\">",
"     8",
"    </a>",
"    ]. The possibility of exacerbating age-related abnormalities should be considered when potentially cardiotoxic drugs are being used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients, particularly those over the age of 75 years, often have multiple other medical conditions at the time of diagnosis of CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common conditions are anemia (often from occult blood loss related to the primary tumor), hypertension, gastrointestinal diagnoses, and heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For seriously ill patients with severe comorbid illness that results in a short life expectancy (particularly one year or less), the risks of chemotherapy often outweigh its benefits. Most of these patients should receive supportive care rather than chemotherapy, with attention to palliation of symptoms.",
"   </p>",
"   <p>",
"    On the other hand, palliative chemotherapy is reasonable for elderly patients with metastatic cancer who have chronic conditions that are not imminently life threatening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quality of life issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life (QOL) is a crucial component of decision-making when treating older cancer patients. The available data suggest that older patients are just as willing to try chemotherapy as their younger counterparts, but less willing to endure severe treatment-related side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data about how chemotherapy affects QOL in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/13\">",
"     13",
"    </a>",
"    ]. A major unanswered issue is whether the higher response rates and generally longer survival seen with modern combination regimens (as compared to a strategy of sequential single agents) are outweighed by the greater likelihood of side effects and adverse impact on QOL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link&amp;anchor=H65#H65\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Combination versus sequential single agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aging process can significantly alter the pharmacokinetics of chemotherapy agents. These pharmacokinetic differences may be caused by alterations in excretion, metabolism, distribution and absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Kidney function and drug excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a gradual decline in kidney function with age in most people, including those without hypertension or known renal disease. This decline results in a significant percent of the elderly population with a calculated glomerular filtration rate (GFR) &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . Impaired renal function can result in higher peak drug levels and more prolonged exposure to chemotherapy, causing excessive toxicity with agents that are dependent upon renal excretion for their clearance (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ), particularly when they are combined with other agents that also are associated with renal dysfunction (eg, NSAIDs).",
"   </p>",
"   <p>",
"    The serum creatinine is",
"    <strong>",
"     not",
"    </strong>",
"    a reliable indicator of renal function in elderly patients, since a reduction in the GFR may be obscured by a simultaneous loss of muscle mass [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Various equations are used to estimate the creatinine clearance; these are based upon measurement of a",
"    <strong>",
"     stable",
"    </strong>",
"    serum creatinine, as well as age and body weight. A calculator is available to calculate the creatinine clearance based upon the ideal body weight and the serum creatinine level (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment of kidney function\", section on 'Glomerular filtration rate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimates of the creatinine clearance rather than the serum creatinine should be used to determine the dosing for chemotherapy drugs that are excreted by the kidneys. General guidelines for the use of chemotherapy agents in patients with compromised renal function are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef56245 \" href=\"UTD.htm?1/42/1708\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H4#H4\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Cytotoxic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver function and metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major pathways are utilized by the liver to detoxify and excrete drugs (",
"    <a class=\"graphic graphic_figure graphicRef59849 \" href=\"UTD.htm?3/9/3230\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In phase I reactions, polar groups are added to drugs by oxidation, reduction, or hydrolysis to facilitate water-solubility. This group of reactions is catalyzed predominantly by the cytochrome P450 enzymes. Many common chemotherapy agents are metabolized through the cytochrome p450 system and the specific isoenzymes responsible for their metabolism are summarized in the individual drug monographs.",
"     </li>",
"     <li>",
"      In phase II reactions, the drug or its metabolite is conjugated to a large water-soluble polar group, such as glucuronide, sulfate, or acetate. This more polar compound is then excreted, either in the bile or by the kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although liver size and hepatic blood flow are decreased with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/17\">",
"     17",
"    </a>",
"    ], these changes are not of sufficient magnitude to require routine dose modification in elderly individuals. However, concurrent hepatic impairment, due to the malignancy or other comorbid conditions, may necessitate dose adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of drugs is affected by body composition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/18\">",
"     18",
"    </a>",
"    ]. In the elderly population, the fat content doubles from approximately 15 to 30 percent of body weight, while intracellular water decreases (33 versus 42 percent in the average 25 year old) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These changes increase peak blood concentrations of more polar drugs while decreasing peak concentrations but lengthening half-lives of lipid-soluble drugs. In addition, decreases in plasma albumin and red blood cell concentration are often present with aging, and this can affect the pharmacokinetics of agents that are bound to albumin or erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These pharmacokinetic alterations in drug distribution in the elderly population have not been shown to necessitate dose modifications based upon age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophy of the intestinal mucosa and decreases in gastrointestinal motility, splanchnic blood flow, and secretion of digestive enzymes all can contribute to a decreased rate of drug absorption in elderly adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/18\">",
"     18",
"    </a>",
"    ]. Although absorption of orally administered drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    may be affected by changes in the gastrointestinal tract, the magnitude of such changes does not justify dose modification based upon age. Furthermore, the emphasis on oral therapy makes compliance an important issue in treatment, as a significant number of patients fail to take oral anticancer therapy as prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMORBIDITY AND FUNCTIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is a highly individualized, multidimensional process. Chronologic age does not reliably predict physiologic decline.",
"   </p>",
"   <p>",
"    The process of aging has been represented as a continuum ranging from functional independence to pre-death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/23\">",
"     23",
"    </a>",
"    ]. At one end of this spectrum, a healthy older individual has no significant limitations in activity and only minimally reduced functional reserve. With progressive increase in comorbidity, an individual becomes more vulnerable and has a decreased functional reserve. This physiologic decline results in significant limitations, although there may be the ability for some recovery. Frailty, the far end of the spectrum, is characterized by severe limitations with little or no ability to withstand treatment or serious illness.",
"   </p>",
"   <p>",
"    Chronologic age alone is not an indication for a change in therapeutic plan or drug dosing in elderly adults. If renal function is normal and there is no significant comorbidity, most chemotherapy agents can be given in full doses. However, dose modifications or a change in the agents used is often required when drug toxicity overlaps with comorbid conditions or there is an increased susceptibility to complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of comorbid conditions that can affect treatment with chemotherapy agents include the following.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Impaired renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy agents that are primarily excreted by the kidneys must be used with extreme care in the elderly population, because of the high incidence of occult renal impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. Guidelines for the use of chemotherapy agents in patients with compromised renal function are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef56245 \" href=\"UTD.htm?1/42/1708\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Kidney function and drug excretion'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hepatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate or severe hepatic dysfunction, due to either comorbidity or tumor, may not be able to metabolize or excrete drugs that are normally handled by the liver, thereby increasing the risk for systemic toxicity. In addition, patients with preexisting liver disease may be susceptible to chemotherapy-induced hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H2#H2\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'General aspects of drug-induced hepatotoxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General guidelines for dose modifications in patients with liver disease are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef69104 \" href=\"UTD.htm?21/11/21694\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=see_link&amp;anchor=H11#H11\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Cytotoxic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ascites and pleural effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extreme caution is indicated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in patients with ascites or pleural effusions, both in elderly and younger patients. Methotrexate accumulates in such third-space fluid collections, which then act as a reservoir for slow distribution into the plasma, thereby increasing systemic exposure and the risk of toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Decreased functional reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased functional reserve can increase the susceptibility to chemotherapy-related complications. Examples of conditions potentially leading to increased toxicity in elderly adults include the following.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow stem cell reserve may decrease with aging. This can contribute to increased hematologic toxicity with myelosuppressive agents, resulting in neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of severe neutropenia is increased in elderly adults compared to younger patients with a variety of chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Severe neutropenia may result in infectious complications, hospitalizations, and a higher mortality.",
"   </p>",
"   <p>",
"    Under most circumstances, decreased doses, rather than white blood cell growth factors, are used to avoid severe neutropenia. Guidelines from the American Society of Clinical Oncology (ASCO) support the use of hematopoietic growth factors when the risk of febrile neutropenia is approximately 20 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/30\">",
"     30",
"    </a>",
"    ]. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend the use of such growth factors for all elderly patients who are being treated with potentially curative regimens such as CHOP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Non-Hodgkin lymphoma'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anemia, which can impair functional status, is commonly seen in patients with cancer, as a complication of both the illness and its treatment with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The incidence of anemia increases significantly with age, both in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The erythropoiesis-stimulating agents (ESAs)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    have been extensively evaluated in cancer patients. The utility of ESAs in patients with nonhematologic malignancies appears to be restricted to those patients in whom the anemia is due to chemotherapy, and there is some evidence that these agents may be harmful in patients with nonhematologic malignancies and anemia not due to chemotherapy. These agents are",
"    <strong>",
"     not",
"    </strong>",
"    indicated for patients being treated with curative intent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preexisting occult heart disease is more frequent in older as opposed to younger patients. The presence of such heart disease can increase the risk of heart failure associated with anthracycline-like agents and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    or coronary artery vasospasm due to fluoropyrimidines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=see_link\">",
"     \"Cardiotoxicity of trastuzumab\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H3#H3\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential risks associated with cardiotoxic chemotherapy in the elderly population were illustrated by a Surveillance, Epidemiology and End Results (SEER) Medicare database study of 9438 patients with diffuse B-cell non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/35\">",
"     35",
"    </a>",
"    ]. The risk of subsequently developing heart failure was increased 29 percent in those whose treatment included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and this increased risk was particularly prominent when anthracyclines were administered to those with hypertension.",
"   </p>",
"   <p>",
"    The risks of cardiotoxicity in elderly adults need to be balanced against the benefits of chemotherapy, and newer methods need to be developed to prevent or treat such toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Polypharmacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older ambulatory patients use approximately three times as many medications as younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/37\">",
"     37",
"    </a>",
"    ]. At least 90 percent of older patients used at least one medication, and the average is at least four medications per patient. The use of large numbers of medications by older patients increases the likelihood of harmful drug interactions, particularly for agents that are metabolized through the cytochrome P450 system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Furthermore, due to the large number of medications used by elderly adults, compliance with therapy is an important issue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/20-22,39,40\">",
"     20-22,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications that inhibit cytochrome P450 enzymes (particularly CYP3A4) have the potential to increase the toxicity of chemotherapy drugs either by reducing its conversion to nontoxic metabolites or by increasing its conversion to toxic metabolites. On the other hand, agents that induce enzymes in the P450 pathway (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , anticonvulsants, alcohol) can decrease the therapeutic effectiveness of a chemotherapy agent by increasing the metabolism of active drug. Other medications that can interact with chemotherapy because of their metabolism by or inhibition of CYP3A4 are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=see_link\">",
"     \"Drugs and the liver: Metabolism and mechanisms of injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug-drug interactions may also be present with herbal remedies and other alternative medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H41#H41\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Interactions of CAM with conventional treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Assessments of physical function and reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients may experience more frequent adverse events during chemotherapy than younger patients, independent of comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/41\">",
"     41",
"    </a>",
"    ]. However, a \"fit elderly\" individual may tolerate standard doses and schedules of chemotherapeutic medications and thus may obtain the same benefit. In contrast, a \"frail elderly\" patient has an increased risk of toxicity, and thus may not be able to tolerate a full course of treatment. In this situation, treatment may need to focus more heavily on improving quality of life, rather than prolonging survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/23,42-45\">",
"     23,42-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The previously described age-related changes in physical health vary widely among individuals. Chronological age is a poor marker of a patient's functional status. Careful assessment of these parameters is required [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/31\">",
"     31",
"    </a>",
"    ]. Several methods of functional assessment are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common method to measure physiologic reserve and functional status in cancer patients is the clinician estimated performance status (PS). There are two widely used scales, Karnofsky Performance Status (KPS) (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 4",
"    </a>",
"    ) and the Eastern Cooperative Oncology Group (ECOG) scale (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Both the ECOG PS and KPS are useful to assess a patient's ability to tolerate chemotherapy and to assess short-term prognosis. Regardless of age, patients with a poor PS (eg, ECOG PS &gt;2, KPS &lt;60) usually tolerate chemotherapy poorly and have a short median overall survival. However, PS tends to underrepresent the degree of functional impairment in the older patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Activities of daily living",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more comprehensive understanding of an older patient's functional state can be obtained by use of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. ADL refers to the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADL refers to the skills required to live independently in the community, including shopping, managing finances, housekeeping, preparing meals, and the ability to take medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Comprehensive geriatric assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of functional status with the ADL and IADL scales is a component of the comprehensive geriatric assessment (CGA) that is used by geriatricians to identify frail older patients at high risk of adverse outcomes such as falls, hospitalization, and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=see_link\">",
"     \"Frailty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Incorporating a more thorough geriatric assessment of function using the CGA can aid treatment decision-making in older cancer patients. As an example, in one report, formal evaluation using a CGA influenced therapeutic decision-making in 82 percent of 161 patients referred for geriatric oncology consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no uniform CGA measurement tool, but all include some multidisciplinary assessment of the following domains: physical function, comorbid conditions, psychological state, social support, cognitive function, nutrition, and polypharmacy (",
"    <a class=\"graphic graphic_table graphicRef68620 \" href=\"UTD.htm?9/13/9436\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Guiding treatment decisions by assessment of physical function",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general agreement that frail older adults, those with significant functional impairment or an ECOG PS of 3 to 4 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ), should be supported with palliative measures aimed at maintaining QOL [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/48\">",
"     48",
"    </a>",
"    ]. There is also general agreement that active, fit, older patients without comorbidity should be treated in the same fashion as younger patients with mCRC (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patients who are neither frail nor fit are the patients in whom treatment decision-making is most complex. Their treatment requires excellent communication and individualized care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1242770806\">",
"    <span class=\"h2\">",
"     Models predicting chemotherapy toxicity and early death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators from the City of Hope combined many of these parameters into a model that can be useful in predicting which patients are at increased risk of developing severe or fatal toxicity from chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef78775 \" href=\"UTD.htm?17/51/18237\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60649 \" href=\"UTD.htm?41/40/42636\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/49\">",
"     49",
"    </a>",
"    ]. Parameters included within this model include age, type of cancer, the proposed chemotherapy regimen, renal and hematologic function, hearing, and activity levels from the comprehensive geriatric assessment (ability to take medications, physical activity, social activity). This approach was significantly better than the physician assessment of Karnofsky Performance Status for predicting chemotherapy toxicity.",
"   </p>",
"   <p>",
"    Other models have been developed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      European investigators studying predictors of early death in older patients treated with first-line chemotherapy for cancer identified advanced disease, a low score on the mini-nutritional assessment, and long Get Up And Go test as being parameters associated with a higher risk of early death (within six months) after initiation of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Investigators at the Moffitt Cancer Center developed a CRASH (Chemotherapy Risk Assessment Scale for High age) score to predict the risk of chemotherapy-related hematologic and nonhematologic toxicity in older persons [",
"      <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/51\">",
"       51",
"      </a>",
"      ]. This model takes into account the specific chemotherapy regimen to be used as well as laboratory values (creatinine, albumin, hemoglobin, LDH, liver function tests) and assessments of functional, mental, and nutritional status. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SPECIFIC MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient age influences the biologic behavior of some malignancies. As examples, acute myeloid leukemia (AML) and aggressive non-Hodgkin lymphoma (NHL) have a poorer prognosis in elderly persons compared to younger individuals. In contrast, breast cancer tends to be somewhat more indolent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic treatment for breast cancer, both as an adjuvant and for metastatic disease, can be used successfully in older women. Such treatment needs to consider both the patient's overall status and potential differences in the natural history of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both systemic hormonal therapy and chemotherapy can have an important role in the management of early breast cancer in elderly adults. In addition to the patient's expected survival, comorbidity, and functional status, a knowledge of the status of regional lymph nodes, primary tumor size, histopathology, estrogen and progesterone receptor status, and whether or not there is expression of",
"    <span class=\"nowrap\">",
"     HER2/neu",
"    </span>",
"    all must be considered in making specific recommendations.",
"   </p>",
"   <p>",
"    Issues surrounding the use of adjuvant therapy for breast cancer in elderly women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=see_link\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of metastatic breast cancer in women &gt;65 years old follows the same principles as in younger women, with a few exceptions. Like younger women, older patients are unlikely to be cured of metastatic disease, and the goal of therapy is palliation rather than cure.",
"   </p>",
"   <p>",
"    Because of the higher frequency of hormone receptor expression and the tendency toward more indolent tumor growth, older women with an unknown hormone receptor status and without life-threatening or rapidly progressive disease should receive a trial of endocrine therapy. If there is a response or a prolonged period of stable disease with the initial endocrine treatment, several different endocrine agents should be tried in succession to maximize quality of life for the longest period of time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of metastatic breast cancer in older women\", section on 'Endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy may be considered when a tumor becomes refractory to endocrine therapy or as first-line therapy if life-threatening or rapidly progressive disease is present. Sequential single agent therapy is often chosen rather than combination chemotherapy in older women with metastatic breast cancer. Bisphosphonates may be particularly useful in women with bone metastases, although particular attention must be paid to potential renal toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of metastatic breast cancer in older women\", section on 'Chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link&amp;anchor=H10#H10\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\", section on 'Breast cancer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H46#H46\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Renal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Colorectal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of cases of colorectal cancer occur in individuals &gt;65 years old. Chemotherapy regimens that incorporate 5-FU or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    are used both as an adjuvant following surgery and for palliation of metastatic disease. Care must be taken in patients with significant cardiovascular disease, because of the potential cardiotoxicity of 5-FU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H3#H3\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Fluorouracil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of enterotoxicity from these agents should also be considered in elderly patients who have undergone bowel surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy and may have altered bowel function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link&amp;anchor=H5#H5\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on '5-Fluorouracil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link&amp;anchor=H8#H8\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Capecitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is underused in patients &gt;65 years old, despite the significant reduction in recurrence and death associated with adjuvant chemotherapy. Although individual trials have provided little information on chemotherapy effectiveness in this population, pooled analyses of data indicate that older patients derive as much benefit from 5-FU-based adjuvant chemotherapy as do younger patients, although the incremental benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    may be less. Treatment-related toxicity is not necessarily worse when close attention is paid to regimen selection. These results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11066?source=see_link\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In elderly patients with metastatic colorectal cancer, pooled results indicate that antitumor efficacy of chemotherapy is similar to that in younger individuals, although there may be a slightly higher rate of hematologic toxicity. Based upon these results, standard 5-FU-based chemotherapy regimens that include either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    are a reasonable option for elderly patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=see_link\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In elderly patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is associated with an increased incidence of delayed diarrhea, due to intestinal accumulation of SN-38, the active metabolite of irinotecan. For this reason, irinotecan should be started at reduced doses in patients &gt;70 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most elderly patients can tolerate the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to these regimens for first-line therapy, although concerns about the potential for thromboembolic complications have tempered enthusiasm for this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status\", section on 'Bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Non-small cell lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slightly more than one-half of patients diagnosed with NSCLC are more than 70 years old. About one-third present with metastatic (stage IV) disease and a majority are not able to undergo potentially curative surgical resection.",
"   </p>",
"   <p>",
"    Chemotherapy is used as an adjuvant after surgical resection for early stage disease, as a component of multimodality therapy for stage III disease, and in first- and second-line therapy to palliate advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy clinical trials in NSCLC have primarily focused upon younger patients. Subset analyses of one trial suggest that adjuvant chemotherapy is as effective in carefully selected elderly patients as it is in those who are younger. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link&amp;anchor=H17#H17\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\", section on 'Elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have established the superiority of concurrent administration of chemotherapy and radiotherapy compared with sequential chemotherapy and RT, and concurrent chemoradiotherapy has become the preferred approach for most unresected patients with pathologic stage III disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link&amp;anchor=H32#H32\">",
"     \"Management of stage III non-small cell lung cancer\", section on 'Concurrent chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although concurrent chemoradiotherapy in elderly patients with stage III NSCLC is associated with an increased incidence of severe toxicity, subset analyses have shown that survival at two and five years is similar to that in younger patients. However, elderly patients managed with chemoradiotherapy may be at increased risk of cardiac disorders even if they were free of such problems prior to the diagnosis of NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link&amp;anchor=H34#H34\">",
"     \"Management of stage III non-small cell lung cancer\", section on 'Elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Palliative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have shown that systemic therapy can improve both survival and quality of life in elderly as well as young patients.",
"   </p>",
"   <p>",
"    Whenever possible, therapy should be individualized based upon molecular and histologic features of the tumor. If feasible, patients should have tumor tissue assessed for the presence of a somatic mutation in the epidermal growth factor receptor (EGFR) that confers sensitivity to the EGFR tyrosine&nbsp;kinase (TK) inhibitors. For elderly patients whose tumor contains an EGFR mutation, initial treatment with an EGFR TK inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ) is preferred rather than chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36455?source=see_link&amp;anchor=H9#H9\">",
"     \"Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status\", section on 'EGFR mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For elderly patients who are candidates for systemic therapy and are EGFR mutation negative or unlikely to respond to an EGFR inhibitor, cytotoxic chemotherapy can improve both survival and quality of life in elderly as well as young patients. For appropriately selected patients with minimal comorbidity and a good performance status who are candidates for chemotherapy, combination chemotherapy rather than single agent chemotherapy may be preferred. For patients who, in the judgment of the treating physician, cannot tolerate combination chemotherapy, single agent therapy may be considered. A number of agents have useful activity in this setting including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Small cell lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with SCLC are &ge;70 years old. Standard chemotherapy regimens have caused increased toxicity in this population although survival was similar to younger patients. In contrast, single agent chemotherapy or dose attenuation caused less toxicity but resulted in inferior survival. Thus, elderly patients should be treated with the same doses and regimens as a younger population if their overall medical condition is satisfactory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H31#H31\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For elderly patients with aggressive NHL, combination chemotherapy using the CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) regimen remains the standard approach because of its curative potential (",
"    <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"     table 9",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is added to CHOP for elderly patients with lymphomas that are positive for CD20 . Although this regimen has significant toxicity, less intense regimens do not appear to be as effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24258?source=see_link&amp;anchor=H4994024#H4994024\">",
"     \"Treatment protocols for lymphoma\", section on 'Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ASCO guidelines recommend that white blood cell growth factors be given to patients &ge;65 years of age with diffuse aggressive lymphoma to permit the administration of full doses of potentially curative chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/30\">",
"     30",
"    </a>",
"    ]. Although the cost-effectiveness of primary as compared to secondary prophylaxis in this setting has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?10/42/10922/abstract/57\">",
"     57",
"    </a>",
"    ], we still agree with the ASCO guidelines and consider that individuals over the age of 65 represent a high-risk group for treatment-related myelosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent NHL in the elderly population is particularly difficult to treat. If a patient cannot tolerate standard salvage chemotherapy, regimens designed particularly for elderly patients may be tried. Alternatively, single agent therapy with anthracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , or alkylating agents may be used for symptom palliation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Regimens for patients ineligible for transplant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long natural history of indolent NHLs and the lack of symptoms at diagnosis have fostered close observation as the initial approach for many of these patients, although chemotherapy options should be considered in selected patients. This approach may be particularly attractive in older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) has a poorer prognosis in older compared to younger patients. However, otherwise healthy, older patients with AML, especially those with favorable cytogenetic features, should be offered curative chemotherapy with standard regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For elderly patients with indolent AML, severe comorbidity, or high risk and unfavorable prognostic factors, intensive chemotherapy may not be the most appropriate choice. In these settings, supportive care with transfusions and control of leukocytosis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Less intensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are important differences in the treatment of advanced cancer in the elderly population, the same principles used in younger patients can be applied if appropriate precautions are taken into account.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacokinetic differences in chemotherapy drug handling in the elderly potentially can contribute to increased toxicity. Particular attention should be given to dosages of drugs that are excreted by the kidneys. Dosages should be modified based upon the calculated creatinine clearance and",
"      <strong>",
"       not",
"      </strong>",
"      the serum creatinine (",
"      <a class=\"graphic graphic_table graphicRef56245 \" href=\"UTD.htm?1/42/1708\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Kidney function and drug excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are accumulating data that some form of assessment is critical to the decision making process for older patients with cancer.",
"      <br/>",
"      <br/>",
"      Extent of comorbidity and functional impairment should be assessed prior to the initiation of treatment and should be incorporated into the overall treatment plan. A comprehensive geriatric assessment can be particularly useful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Comorbidity and functional status'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Comprehensive geriatric assessment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Prospective studies suggest that simple clinical measures may be able to predict chemotherapy toxicity and mortality. (See",
"      <a class=\"local\" href=\"#H1242770806\">",
"       'Models predicting chemotherapy toxicity and early death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the healthy elderly patient with minimal comorbidity and near-normal functional reserve, aggressive treatment including full doses of chemotherapy is warranted and can yield results that are similar to those in younger patients. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Breast cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Colorectal carcinoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Non-small cell lung cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H40\">",
"       'Small cell lung cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41\">",
"       'Non-Hodgkin lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The use of white blood cell growth factors may permit the clinician to maintain dose intensity and avoid severe neutropenia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bone marrow'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H41\">",
"       'Non-Hodgkin lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythropoietin may be useful to treat preexisting or chemotherapy-induced anemia. However, these agents are",
"      <strong>",
"       not",
"      </strong>",
"      indicated for patients being treated with curative intent. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Bone marrow'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"       \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the frail elderly patient, therapeutic goals may need to focus primarily on quality of life and symptom palliation, rather than prolonging survival. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Comorbidity and functional status'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/1\">",
"      Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004; 31:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/2\">",
"      Lichtman SM. Therapy insight: Therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol 2006; 3:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/3\">",
"      Castell&oacute;n TD, Sieving KE. An experimental test of matrix permeability and corridor use by an endemic understory bird. Conserv Biol 2006; 20:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/4\">",
"      Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003; 21:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/5\">",
"      Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/6\">",
"      Kumar A, Soares HP, Balducci L, et al. Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007; 25:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/7\">",
"      Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012; 30:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/8\">",
"      Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/9\">",
"      Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/10\">",
"      Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know? Cancer 1994; 74:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/11\">",
"      Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/12\">",
"      Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/13\">",
"      Sanoff HK, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer 2007; 6:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/14\">",
"      Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/15\">",
"      Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/16\">",
"      Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/17\">",
"      Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/18\">",
"      Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997; 13:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/19\">",
"      Schrijvers D, Highley M, De Bruyn E, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/20\">",
"      Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/21\">",
"      Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/22\">",
"      Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/23\">",
"      Hamerman D. Toward an understanding of frailty. Ann Intern Med 1999; 130:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/24\">",
"      Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/25\">",
"      Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 2000; 14:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/26\">",
"      Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/27\">",
"      G&oacute;mez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/28\">",
"      Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/29\">",
"      Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/30\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/32\">",
"      An&iacute;a BJ, Suman VJ, Fairbanks VF, et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 1997; 45:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/33\">",
"      Chaves PH, Ashar B, Guralnik JM, Fried LP. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluated? J Am Geriatr Soc 2002; 50:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/34\">",
"      An&iacute;a BJ, Suman VJ, Fairbanks VF, Melton LJ 3rd. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc 1994; 69:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/35\">",
"      Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:3159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/36\">",
"      Carver JR, Schuster SJ, Glick JH. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. J Clin Oncol 2008; 26:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/37\">",
"      Vestal RE. Aging and pharmacology. Cancer 1997; 80:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/38\">",
"      Kivist&ouml; KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/39\">",
"      Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park) 2008; 22:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/40\">",
"      Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006; 17:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/41\">",
"      Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/42\">",
"      Rockwood K, Stadnyk K, MacKnight C, et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999; 353:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/43\">",
"      Repetto L, Comandini D, Mammoliti S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit Rev Oncol Hematol 2001; 37:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/44\">",
"      Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/45\">",
"      Balducci L, Stanta G. Cancer in the frail patient. A coming epidemic. Hematol Oncol Clin North Am 2000; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/46\">",
"      Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007; 25:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/47\">",
"      Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/48\">",
"      Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/49\">",
"      Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/50\">",
"      Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012; 30:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/51\">",
"      Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118:3377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/52\">",
"      Carlson RW, Moench S, Hurria A, et al. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw 2008; 6 Suppl 4:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/53\">",
"      Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/54\">",
"      Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/55\">",
"      Hardy D, Liu CC, Cormier JN, et al. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010; 21:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/56\">",
"      Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in elderly patients. Cancer 2010; 116:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/42/10922/abstract/57\">",
"      Chan KK, Siu E, Krahn MD, et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol 2012; 30:1064.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2823 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10922=[""].join("\n");
var outline_f10_42_10922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHALLENGES SPECIFIC TO ELDERLY PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age-related organ function decline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bone marrow function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quality of life issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Kidney function and drug excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver function and metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMORBIDITY AND FUNCTIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Impaired renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hepatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ascites and pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Decreased functional reserve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Polypharmacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Assessments of physical function and reserve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Performance status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Activities of daily living",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Guiding treatment decisions by assessment of physical function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1242770806\">",
"      Models predicting chemotherapy toxicity and early death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SPECIFIC MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Colorectal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Stage III disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Palliative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2823|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/9/3230\" title=\"figure 1\">",
"      Hepatic drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/42/1708\" title=\"table 1\">",
"      Chemo dose adj renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/11/21694\" title=\"table 2\">",
"      Chemo dose modify liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 3\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/13/9436\" title=\"table 6\">",
"      Elements comp geri assess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/51/18237\" title=\"table 7\">",
"      Model for predicting chemotherapy toxicity in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/40/42636\" title=\"table 8\">",
"      Risk score versus physician-rated KPS chemo toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 9\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11066?source=related_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13754?source=related_link\">",
"      Drugs and the liver: Metabolism and mechanisms of injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36455?source=related_link\">",
"      Systemic therapy for advanced non-small cell lung cancer in elderly patients and patients with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41466?source=related_link\">",
"      Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40903?source=related_link\">",
"      Treatment of metastatic breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24258?source=related_link\">",
"      Treatment protocols for lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_42_10923="Treatment of parvovirus B19";
var content_f10_42_10923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for symptomatic parvovirus B19 infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema infectiosum",
"       </td>",
"       <td>",
"        None or symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis or arthralgia",
"       </td>",
"       <td>",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient aplastic crisis",
"       </td>",
"       <td>",
"        Transfusions and oxygen, if needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal hydrops",
"       </td>",
"       <td>",
"        Intrauterine blood transfusion (?)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic infection with anemia",
"       </td>",
"       <td>",
"        Intravenous immune globulin and transfusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic infection without anemia",
"       </td>",
"       <td>",
"        Intravenous immune globulin (?)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10923=[""].join("\n");
var outline_f10_42_10923=null;
var title_f10_42_10924="Helminths with prolonged eos";
var content_f10_42_10924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helminthic parasitic diseases causing eosinophilia of years duration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parasite",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hookworm infection",
"       </td>",
"       <td>",
"        Common cause of low-grade eosinophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strongyloidiasis",
"       </td>",
"       <td>",
"        Self-perpetuating, auto-infection cycle; may last &gt;50 yrs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cysticercosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echinococcosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Filariases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tropical pulmonary eosinophilia",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Loiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        Especially in expatriates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Onchocerciasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mansonelliasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Flukes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Schistosomiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fas",
"        <span class=\"sublist1\">",
"         c",
"        </span>",
"        ioliasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clonorchiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paragonimiasis",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weller, PF. Med Clin North America 1992; 76:1413.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10924=[""].join("\n");
var outline_f10_42_10924=null;
var title_f10_42_10925="Painful neuropathies";
var content_f10_42_10925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary types of painful sensory neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual clinical setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic small fiber neuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Prevalence increases with age",
"        </p>",
"        <p>",
"         Normal strength and deep tendon reflexes",
"        </p>",
"        <p>",
"         Normal position and vibration sensation",
"        </p>",
"        <p>",
"         Diminished pin sensation in lower extremities",
"        </p>",
"        <p>",
"         Normal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Diminished sudomotor function",
"        </p>",
"        <p>",
"         Abnormal skin biopsy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diabetic peripheral neuropathy",
"       </td>",
"       <td>",
"        <p>",
"         History or family history of diabetes",
"        </p>",
"        <p>",
"         Obesity, hypertension",
"        </p>",
"        <p>",
"         Diminished deep tendon reflexes",
"        </p>",
"        <p>",
"         Diminished distal sensation",
"        </p>",
"        <p>",
"         Usually abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Impaired glucose tolerance, impaired fasting glucose, elevated hemoglobin A1C",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hereditary neuropathies",
"       </td>",
"       <td>",
"        <p>",
"         Family history",
"        </p>",
"        <p>",
"         Pes cavus or hammer toe",
"        </p>",
"        <p>",
"         Usually diminished deep tendon reflexes",
"        </p>",
"        <p>",
"         Diminished distal sensation",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Neuropathy related to connective tissue disease",
"       </td>",
"       <td>",
"        <p>",
"         History of rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, Sj&ouml;gren syndrome",
"        </p>",
"        <p>",
"         Diminished deep tendon reflexes",
"        </p>",
"        <p>",
"         Diminished distal sensation",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Positive for autoimmune antibodies",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vasculitic neuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Known systemic vasculitis (but vasculitic neuropathy may occur in isolation)",
"        </p>",
"        <p>",
"         Multifocal examination findings",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Positive for autoimmune antibodies, hepatitis B or C, cryoglobulins",
"        </p>",
"        <p>",
"         Abnormal nerve biopsy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Neuropathy associated with monoclonal gammopathy",
"       </td>",
"       <td>",
"        <p>",
"         Prevalence increases with age",
"        </p>",
"        <p>",
"         Variable examination findings depending upon mode of presentation (mononeuritis multiplex, distal polyneuropathy, radiculopathy, or plexopathy)",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Monoclonal gammopathy (often IgM)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Paraneoplastic sensory neuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Tobacco smoking, family history, asbestos exposure",
"        </p>",
"        <p>",
"         Solid tumor cancer (mainly lung)",
"        </p>",
"        <p>",
"         Diminished deep tendon reflexes",
"        </p>",
"        <p>",
"         Diminished distal sensation",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Anti-Hu antibodies",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Familial or acquired amyloid polyneuropathy",
"       </td>",
"       <td>",
"        <p>",
"         Family history or known plasma cell dyscrasia (acquired form)",
"        </p>",
"        <p>",
"         Diminished deep tendon reflexes",
"        </p>",
"        <p>",
"         Sensory loss",
"        </p>",
"        <p>",
"         Autonomic dysfunction (eg, postural hypotension, impotence, bladder dysfunction)",
"        </p>",
"        <p>",
"         Compressive mononeuropathy (mainly carpal tunnel syndrome)",
"        </p>",
"        <p>",
"         Abnormal electrodiagnostic testing",
"        </p>",
"        <p>",
"         Monoclonal gammopathy (acquired form)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NCS: nerve conduction study.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. N Engl J Med 2003; 348:1243.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10925=[""].join("\n");
var outline_f10_42_10925=null;
var title_f10_42_10926="Contents: Adult and Pediatric Emergency Medicine";
var content_f10_42_10926=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Adult and Pediatric Emergency Medicine",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adult and Pediatric Emergency Medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?7/61/8158\">",
"         Adult environmental emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/24/42372\">",
"         Adult medical emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/1/35871\">",
"         Adult orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/30/37358\">",
"         Adult procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/58/11182\">",
"         Adult resuscitation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/58/43950\">",
"         Adult signs and symptoms",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/48/36622\">",
"         Adult toxicology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?25/57/26526\">",
"         Adult trauma",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?33/3/33853\">",
"         Emergency med calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/42/28333\">",
"         Emergency medical services/Disaster medicine",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/20/26957\">",
"         Pediatric EMS",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/36/590\">",
"         Pediatric medical emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/36/591\">",
"         Pediatric orthopedics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/52/1871\">",
"         Pediatric procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/19/7486\">",
"         Pediatric resuscitation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/50/11055\">",
"         Pediatric signs and symptoms",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?42/20/43341\">",
"         Pediatric surgical emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/18/37166\">",
"         Pediatric toxicology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/10/3232\">",
"         Pediatric trauma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/21/1374\">",
"         Peds environmental emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?6/49/6942\">",
"         Peds psychosocial emergencies",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/18/41253\">",
"         What's new in adult and pediatric emergency medicine",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-128628341B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_42_10926=[""].join("\n");
var outline_f10_42_10926=null;
var title_f10_42_10927="Aortic stenosis short axis echocardiogram";
var content_f10_42_10927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/71087/aosshtec_conv.mp4?title=Aortic+stenosis+short+axis+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcific aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Short axis view of 2-D echocardiogram showing echo dense calcified aortic valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_42_10927=[""].join("\n");
var outline_f10_42_10927=null;
